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Thymoquinone (TQ) is a natural compound isolated from the seed oil of 
Nigella sativa, a traditional herb native to Southwest Asia. Many types of 
carcinoma, for example lung, colon, liver and prostate, were found to be 
inhibited by TQ. However, the mechanism of the inhibitory effect of TQ on 
breast cancer is unclear. As such, in the present study, the effects of TQ on 
breast carcinoma were investigated both in vitro and in vivo. TQ was found to 
inhibit the growth of MCF-7, MDA-MB-231 and BT-474 breast cancer cells 
in a dose- and time-dependent manner. This growth inhibition could be further 
enhanced by combining TQ with known chemotherapeutic drugs, such as 
doxorubicin and 5-fluorouracil. No cell cycle arrest was observed after TQ 
treatment, however, subG1 accumulation was detected indicating apoptosis 
induction. Indeed, increased percentage of annexin V positive cells and 
increased PARP protein cleavage were observed after TQ treatment. In 
addition to apoptosis induction, TQ was able to inhibit breast cancer cell 
migration and invasion.  
TQ was found to induce PPAR-γ activity in a dose- and time-dependent 
manner. Pre-treatment with GW9662, a PPAR-γ specific inhibitor, could 
abrogate TQ-induced PPAR-γ activity and TQ-induced apoptosis. Moreover, 
treatment with GW9662 and PPAR-γ dominant negative could reverse the 
decrease of survivin mRNA and protein levels induced by TQ. These results 
suggest that TQ suppressed survivin expression via PPAR-γ induction.  
We found that TQ was able to induce ROS production in breast cancer cells in 
a time-dependent manner. This induction could be reversed by pre-treatment 
with N-acetylcysteine (NAC), a strong antioxidant. The growth inhibition and 
pro-apoptotic effects of TQ could also be abrogated by NAC. Moreover, the 
decrease of anti-apoptotic proteins, such as survivin, XIAP, Bcl-2 and Bcl-xL, 
induced by TQ could also be reversed by NAC. We also found that PPAR-γ 
could be the downstream effector of ROS in the mechanism of action of TQ.  
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TQ was found to increase p38 phosphorylation, whereby this induction could 
be reversed by pre-treatment with SB203580, a p38-specific inhibitor. 
Moreover, the growth inhibition and pro-apoptotic effects of TQ in breast 
cancer cells could also be abrogated by SB203580. The pro-apoptotic role of 
TQ-induced p38 activation was also confirmed by p38 siRNA gene silencing. 
We found that TQ-induced ROS production was able to affect p38 
phosphorylation but not vice versa. In MCF-7 cells, PPAR-γ and p38 appeared 
to antagonize each other in the mechanism of action of TQ. 
In addition, TQ was able to suppress breast tumor growth in nude mice and 
combined with doxorubicin to produce greater suppression. Reduced cell 
proliferation and increased apoptosis were found in the tumor tissues of TQ-
treated mice. Moreover, TQ increased the hepatic level of anti-oxidant 
enzymes/molecules (catalase, superoxide dismutase and glutathione) in these 
mice. 
Taken together, the present study demonstrates the potential anticancer 
activities of TQ in human breast carcinoma. ROS, PPAR-γ and p38 pathways 
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1.1 Breast cancer: epidemiology and risk factors 
Breast cancer is a type of cancer occurring at breast tissue, and this type of 
cancer is more common in female population than male. There are two types 
of breast cancer namely ductal carcinoma and lobular carcinoma. Ductal 
carcinoma is originating from breast ducts, which are tubes that move milk 
from the breast to nipple. Lobular carcinoma is originating from lobules, the 
parts of the breast that produce milk. Classification of breast cancer is based 
on several aspects such as histopathology, grade, stage, DNA classification 
(gene mutation such as BRCA1/2 and p53) and receptor status (estrogen 
receptor (ER), progresterone receptor (PR) and human epidermal growth 
factor receptor 2 (HER2)). Classification of breast cancer is important for 
physicians to design appropriate regimen to treat breast tumor. Triple-negative 
breast cancer refers to breast cancer that demonstrated the absence of ER and 
PR, as well as the lack of HER2 over-expression. This type of breast cancer 
accounts for 10-20% of invasive breast cancer cases (Boyle, 2012). Luminal-A 
breast cancers represent ER-positive and/or PR-positive but HER2-negative, 
while luminal-B breast cancers exhibit ER-positive and/or PR-positive as well 
as HER2-positive. HER2 over-expressing breast cancers are ER-negative and 
PR-negative but HER2-positive. “Basal-like” breast cancers are defined as 
ER-negative, PR-negative, HER2 negative, cytokeratin 5/6 positive and/or 
epidermal growth factor receptor positive (Boyle, 2012).  
According to the global cancer statistic by Jemal et al., breast cancer showed 
the highest number of estimated new cases (23%) and estimated deaths (14%) 
than other types of cancer in female population worldwide (Jemal et al., 2008). 
The incidence of breast cancer is relatively higher in developed 
countries/regions including Western and Northern Europe, North America, 
Australia and New Zealand (Jemal et al., 2008). In Singapore, breast cancer is 
the commonest cancer in females follow by colo-rectum and lung cancer (Teo 
and Soo, 2013). The age-standardized rate of breast cancer in Singapore is 
60/100,000 at recent years (Teo and Soo, 2013), increased dramatically from 
20/100,000 in 1968-1972 (Singapore Cancer Registry). The age-standardized 
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mortality rate of breast cancer is 14.1/100,000, which is the highest among 
other cancers in Singapore females (Teo and Soo, 2013). In a life time, 1 in 16 
of Singaporean women will be diagnosed with breast cancer, compared to 1 in 
8 women in Western countries.  
There are many risk factors in breast cancer such as age and gender, gene 
mutations, family history, early menarche, late menopause and alcohol intake 
(Key et al., 2001; Higa, 2009). From epidemiological studies, obesity has been 
associated with increased risk of cancer including breast, kidney, pancreas and 
liver cancer (World Cancer Research Fund/American Institute for Cancer 
Research 2007). Adipose tissues express sex-steroid metabolizing enzyme 
such as aromatase that can increase the formation of estrogens from 
androgenic precursors (Renehan et al., 2006). Higher level of pro-
inflammatory cytokines, such as TNF-α, IL-2 and IL-10, are associated with 
body adiposity (Vucenik and Stains, 2012). The conclusion that obesity leads 
to poorer prognosis can be explained by a meta-analysis study reported that 
breast cancer patients who were obese at the time of diagnosis had 33% higher 
rate of cancer-specific and overall mortality compared to non-obese patients 
(Protani et al., 2010). Indeed, patients with triple-negative breast cancer were 
more likely being overweight (Kwan et al., 2009). Furthermore, physically 
active women showed 25% lower in breast cancer risk compared to the least 
active women (Lynch et al., 2011). A large scale case-referent study in Japan 
had reported that women who exercised for healthy life twice or more per 
week had reduced risk of breast cancer, and this protection was greater in high 
BMI women (OR=0.57) than medium BMI women (OR=0.71) (Hirose et al., 
2003).  
In addition, childbirth is able to reduce the risk of breast cancer, with greater 
protection for early first birth and large number of childbearing (Key et al., 
2001). A re-analysis of 47 epidemiological studies in 30 countries showed that 
the relative risk of breast cancer could be reduced by 4.3% with every 12 
months of breastfeeding, and 7% for each childbirth (Collaborative Group on 
Hormonal Factors in Breast Cancer 2002). This report also suggested that the 
shorter duration of breastfeeding in developed countries might partly 
responsible for the high incidence rate of breast cancer in these countries.   
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Smoking is a well-known risk factor for several types of malignancy namely 
lung, breast and head and neck cancer (Ligibel, 2012). It had been reported 
that the relative risk of breast cancer of current smokers versus never smokers 
was 1.7 in Japan population (Nagata et al., 2006). A recent study of 300,000 
Norwegian women reported that ever smokers had 15% increased risk of 
breast cancer compared to never smokers (Bjerkaas et al., 2013). Interestingly, 
smokers who started to smoke after the first childbirth did not showed 
significant difference in breast cancer risk compared to never smokers 
(Bjerkaas et al., 2013).  
Migrant and other ecological studies showed that people migrated from areas 
of low breast cancer incidence to areas of high breast cancer incidence would 
acquire the risk of the indigenous population in one or two generations 
(Nelson, 2006). These studies suggested that the environmental factors, such 
as diet and life-styles, were able to affect the risk of breast cancer because the 
genetic pool of a population won’t deviate much in one or two generations 
(Vera-Ramirez et al., 2013). Indeed, high consumption of meat, particularly 
red meat, has been associated with increased risk of breast cancer (Zheng and 
Lee, 2009), with Indonesia OR=8.47, Taiwan OR=5.1 and China OR=2.9 
(Park et al., 2008). This could be due to the excessive exposure to sex 
hormone through the consumption of meat derived from animals treated with 
sex hormones. In addition, the intake of animal fat was found to increase 
hormone level, which in turn, increased the risk of breast cancer (Vera-
Ramirez et al., 2013). The study of 15,351 female subjects showed that 
women in high consumption of processed meat, butter, fish and other animal 
fats, as well as low consumption of bread and fruit juices, exhibited 2-fold 
higher risk of breast cancer (Schulz et al., 2008). Moreover, alcohol intake is 
also associated with increased incidence of breast cancer, particularly ER-
positive, which could be due to the increase in the level of serum sex 
hormones (Zhang et al., 2007). 
Cyclin D1 plays an important role in cell cycle progression, particularly G1 to 
S phase, by forming active enzyme complexes with cyclin-dependent kinases 
4/6 (Matsushime et al., 1994). It was found that cyclin D1 was overexpressed 
in 50% of breast tumors (Velasco-Velázquez et al., 2011). This protein 
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negatively correlated with overall survival and relapse-free survival in breast 
cancer patients (Umekita et al., 2002). Interestingly, breast tumors with cyclin 
D1 overexpression were mostly estrogen receptor positive (Kenny et al., 1999). 
Breast cancer patients expressing low/moderate level of cyclin D1 showed 
higher response and better survival rate in tamoxifen therapy (Stendahl et al., 
2004; Jirstrom et al., 2005). This might explain the failure of anti-estrogen 
therapy in some tumors despite they were ER-positive. In addition of its role 
in cell cycle progression, cyclin D1 can act as transcription regulator (Roy and 
Thompson, 2006). For example, cyclin D1 was shown to activate estrogen 
receptor signaling via ligand-independent fashion (Zwijsen et al., 1997). 
Moreover, cyclin D1 is able to interact with different transcription factors such 
as androgen receptor, DMP1 and C/EBPβ (Coqueret, 2002). 
Mutations of genes which involved in DNA damage repair, chromosome 
remodeling and cell cycle progression, such as BRCA1 and BRCA2, are 
associated to about 10% breast cancer cases (Bayraktar and Glück, 2012). 
Women with BRCA1/2 mutations showed three times higher risk in 
developing breast cancer compared to general population (Liebens et al., 
2007). BRCA1 is located at chromosome 17q21, while BRCA2 is 13q12.3. 
Point mutation in these genes can cause frameshift, nonsense and missense 
mutations (Cao et al., 2013). BRCA1 protein plays a role in repairing gene 
mutations, while BRCA2 protein is involved in the repair of chromosomal 
damage. Lifetime risk of developing breast cancer for women with BRCA1 
mutation is 60-70%, while BRCA2 mutation is 40-60% (King et al., 2003; 
Antoniou et al., 2003). BRCA1 mutation carriers showed lower short-term and 
long-term overall survival rates than non-carriers (Lee et al., 2010). Among 
carriers with BRCA1 mutation, one-third were triple-negative breast cancer 
(Peshkin et al., 2010). Tumors with BRCA2 mutation usually expressed 
estrogen receptor and progresterone receptor, unlike BRCA1 mutation 
(Lakhani et al., 1998). Loss of BRCA1/2 functions could lead to chromosomal 
instability, which in turn, promoting tumorigenesis (Dhillon et al., 2011). 
BRCA1/2 mutation cancer cells were unable to repair DNA damages through 
homologous recombination (Moynahan et al., 1999), thus they were sensitive 
to inter-strand DNA cross-linking agents such as cisplatin. However, there are 
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studies reported that these cancer cells could acquire resistance to such 
chemotherapy agents by restoring BRCA1/2 functions via secondary 
BRCA1/2 mutations (Dhillon et al., 2011). Therefore, BRCA1/2 mutation 
carriers are recommended to undertake a particular surveillance protocol 
starting age of 30 to detect the onset of breast cancer (Apostolou and Fostira, 
2013). Recently, there are increasing studies reporting the efficacy of 
Poly(ADP-ribose)polymerase inhibitors in patients with BRCA1/2 mutation, 
and several potential drug candidates of this class are currently in phase I/II 
clinical investigation (Lee et al., 2014).  
TP53 gene, which encodes p53 protein, is an important gene that regulates cell 
cycle progression, DNA repair, cell senescence and apoptosis. This gene has 
been described as “guardian of the genome” for its role in conserving stability 
by preventing genome mutation. It has been reported that more than 50% of 
human tumors contained a mutation or deletion of TP53 gene (Hollstein et al., 
1991). TP53 mutations are mostly missense point mutations that located in the 
central region encoding the DNA binding domain (Varna et al., 2011; Soussi 
et al., 2006). Some of the molecular targets of p53 are tsp1, p21, GADD45, 
Puma and Noxa. In addition to p53, there are another two members of p53 
family, namely p63 and p73, which share the same functional domains of p53 
(Lai et al., 2012). p53 plays an important role in regulating cellular redox 
status. Under normal physiological condition, low level of p53 suppresses 
ROS, while high level of p53 induces ROS accumulation in response to 
cellular stress (Vurusaner et al., 2012). Increased ROS will promote apoptotic 
cell death. Mutation to TP53 gene will cause a disease known as Li-Fraumeni 
syndrome. These patients are at high risk to develop cancer, which is 50% at 
age of 40 and up to 90% at age of 60 (Birch et al., 1998). Females with TP53 
mutation are at high risk to develop breast cancer and 5% of these cases were 
occurred before the age of 30 (Gonzalez et al., 2009). It was shown that triple-
negative breast cancer has increased frequency of TP53 mutation (Chae et al., 
2009). 
PTEN is a tumor suppressor gene because it can regulate PI3K/Akt pathway 
that is frequently involved in cancer survival and cell proliferation. Mutation 
of PTEN gene, which will cause Cowden syndrome, predisposed carriers to 
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several types of cancer including breast cancer, endometrial cancer and 
thyroid carcinoma (Li et al., 1997). Indeed, females with PTEN mutation have 
50% lifetime risk to develop breast cancer (Apostolou and Fostira, 2013). In 
addition to BRCA1/2, TP53 and PTEN, there are other high-penetrant genes 
such as STK11 (serine/threonine kinase 11) and CDH1 (cadherin 1). Mutation 
of STK11 gene increased the risk of developing cancer to up to 85% (Hearle et 
al., 2006). Women with CDH1 mutation displayed 40–54% lifetime risk of 
developing lobular breast cancer (Kaurah et al., 2007).     
In addition of loss-of-function in tumor suppressor genes, gain-of-function in 
oncogenes can also lead to tumorigenesis. Oncogenes such as ErbB2, PI3KCA, 
Myc and CCND1 are often deregulated in breast cancer (Lee and Muller, 
2010). 20-30% of breast cancer cases exhibited increased level of HER2 due 
to gene amplification of ErbB2 (Slamon et al., 1989). Overexpression of 
ErbB2 often leads to aggressive tumor type (Lee and Muller, 2010). Moreover, 
there are studies showed that miR-155 was oncogenic in many types of tumor 
including breast (Wang and Wu et al., 2012). 
 
 
Figure 1.1: Factors that influence the risk of development of breast cancer. 




1.2 Breast cancer: chemoprevention and treatment 
Early signs of breast cancer include lump in breast area, change in nipple 
appearance, fluid leaking from the nipple and skin dimpling. After detection of 
signs and symptoms of breast cancer, imaging tests such as mammogram and 
magnetic resonance imaging scan will be used to further examine for breast 
disease. If these exams suggest the possibility of breast cancer, biopsy will 
eventually be used to confirm the disease. The tissues removed for biopsy will 
be analyzed by pathologist to classify breast cancer on several aspects such as 
type, grade and receptor status. This information will allow physicians to 
design appropriate treatment regimen to target the disease. For example, triple-
negative breast cancers that usually led to poorer prognosis and higher risk of 
recurrence would receive greater attention from the physicians (Boyle, 2012). 
A number of studies showed that breast screening could effectively lead to 
early detection of the disease, which in turn, resulting in an increase in breast 
cancer survival (Wang et al., 2011b). In the present, the treatments for breast 
cancer include surgery, radiation therapy, chemotherapy, hormone therapy and 
targeted therapy (Higa, 2009). Surgery is to physically remove tumor tissue, 
either lumpectomy or mastectomy. Lumpectomy removes the breast tumor 
with a margin of surrounding normal tissue, while mastectomy removes the 
entire breast and possibly nearby tissue.  
Radiation therapy is to apply ionizing radiation on tumor area to control or kill 
cancerous cells. This type of therapy is normally given to the whole breast, 
while in certain cases it is also given to areas of lymph node close to the breast. 
Radiation therapy may be given before surgery to shrink the tumor or after 
surgery to kill any remaining cancer cells. Radiation therapy achieved high 
cure rate if distant metastasis has not occurred (Langlands et al., 2013).  
Chemotherapy is to use chemotherapeutic drugs to kill highly replicating 
malignant cells, and it is normally given for patients with invasive and 
metastatic breast cancer. This type of therapy usually runs for 3-6 months and 
it is relatively well-tolerated in most women (Thomson et al., 2012). 
Neoadjuvant chemotherapy is given prior to surgery or radiation therapy for 
the purpose of tumor shrinking, which allows the later operation more feasible 
8 
 
and less destructive. Adjuvant chemotherapy is given after surgery to destroy 
remaining cancerous cells and prevent recurrence. Some of the examples of 
chemotherapeutic agent are doxorubicin, cyclophosphamide, paclitaxel and 5-
fluorouracil (Lai et al., 2012). Doxorubicin is a DNA intercalating agent that is 
used in many different types of cancer including breast, lung, stomach and 
leukemia. It can stabilize topoisomerase II after this enzyme has broken the 
DNA chain for replication, whereby this will prevent DNA strands from being 
resealed and thus stopping DNA replication (Pommier et al., 2012). 
Cyclophosphamide is a nitrogen mustard alkylating agent that is first 
converted in liver to form active metabolites for its chemotherapeutic effect. 
The active metabolite, phosphoramide mustard, can form irreversible DNA 
crosslinks between and within DNA strands, which in turn, resulting in 
apoptotic cell death. Paclitaxel is a mitotic inhibitor used in cancer therapy for 
breast, ovarian and lung carcinoma. This drug can stabilize microtubules by 
interfering with the breakdown of microtubules during cell division 
(Bharadwaj and Yu, 2004). 5-fluorouracil is a pyrimidine analog that acts as a 
thymidylate synthase inhibitor. After administration, this drug can incorporate 
into DNA to prevent DNA synthesis, which in turn, resulting in cell cycle 
arrest and apoptosis. Tumors with TP53 mutation has been associated with 
poor response to chemotherapy (Varna et al., 2011).  
The main idea of hormone therapy is to block estrogen hormone from 
supporting tumor growth, and this therapy is normally given for patients with 
ER-positive breast cancer. For example, tamoxifen can block ER from its 
ligand, while anastrozole (aromatase inhibitor) can block estrogen production 
(Cazzaniga and Bonanni, 2012). Tamoxifen is a prodrug, whereby it is 
metabolized in the liver by cytochrome P450 isoforms CYP2D6 and CYP3A4 
to produce active metabolite 4-hydroxytamoxifen (Desta et al., 2004). 4-
hydroxytamoxifen binds to ER to prevent the transcription of estrogen-
responsive genes. Anastrozole can inhibit aromatase, which is the enzyme that 
involved in the conversion of androgen to estrogen. About 80% of breast 
cancers rely on hormone estrogen to grow, thus the inhibition of estrogen 
synthesis serves a good treatment strategy.   
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Targeted therapy, also known as biologic therapy, is to use special designed 
drug to target protein molecules that are involved in tumorigenesis. There are 
two main types of targeted therapy namely monoclonal antibody (e.g. 
trastuzumab and pertuzumab) and tyrosine kinase inhibitor (e.g. lapatinib) 
(Cazzaniga and Bonanni, 2012). HER2 over-expression can promote cell 
proliferation via PI3K/Akt pathway. Trastuzumab can bind to the domain IV 
of HER2 causing HER2 down-regulation. This will in turn interfere with Akt 
signaling (Kute et al., 2004). Slamon et al. reported that the combination of 
trastuzumab and standard chemotherapy produced greater clinical benefits 
including longer time to disease progression, higher response rate, longer 
survival and 20% reduction in death risk (Slamon et al., 2001). On the other 
hand, lapatinib can bind to the ATP-binding pocket of EGFR/HER2 protein 
kinase domain preventing self-phosphorylation, which in turn, resulting in the 
inhibition of subsequent downstream signaling (Nelson and Dolder, 2006).    
In addition of treatment, more and more studies searched for effective ways to 
prevent or reduce breast cancer cases. Chemoprevention is defined as the use 
of natural, synthetic or biochemical agents to prevent, reverse or suppress 
carcinogenic process from developing into neoplastic disease (Cazzaniga and 
Bonanni, 2012). Since long term administration of a drug may cause side 
effect to the human body, chemoprevention is recommended to people with 
high risk to develop cancer. For carriers with BRCA1/2 mutations, yearly 
mammography and bilateral breast MRI screening are recommended starting 
at age of 25-30 (Kriege et al., 2004). Generally, breast cancer 
chemoprevention can be divided into two categories, namely ER-positive and 
ER-negative. For ER-positive breast cancer prevention, two major classes of 
agent are selective estrogen receptor modulators (e.g. tamoxifen and 
raloxifene) and aromatase inhibitors (e.g. anastrozole and exemestane). The 
first chemoprevention drug to receive FDA approval is tamoxifen, of which it 
can reduce the risk of breast cancer as much as one-half. Although the 
therapeutic efficacy of raloxifene is lower than tamoxifen, it is less toxic and 
does not increase the risk of endometrial cancer (Umar et al., 2012). The data 
from adjuvant trials suggested that aromatase inhibitors decreased the 
incidence of breast cancer by 40-50% (Cuzick, 2005). In contrast of ER-
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positive breast cancer prevention, the main idea of ER-negative breast cancer 
prevention is to target certain cellular signaling pathways involved in 
carcinogenesis. Several classes of agent are used such as nuclear receptors (e.g. 
PPAR-γ), anti-inflammatory and antioxidant (e.g. COX-2), and membrane 
receptors and signal transduction (e.g. HER-2 and tyrosine kinase) (Cazzaniga 
and Bonanni, 2012). Nevertheless, there are studies looking at immunotherapy 
for cancer prevention, for example vaccines are used to target tumor-
associated or tumor-specific antigens (Umar et al., 2012).  
 
 
1.3 Breast cancer: limitations of current cancer treatment 
Despite the effectiveness of anticancer agents in treating breast cancer, their 
applications are often limited by the toxicities caused by these agents. These 
toxicities may result in organ damage and even fatal in extreme cases.  
Even though surgery is a good way to remove a solid tumor, however, post-
mastectomy pain syndrome might occur in 20-30% of patients who had 
mastectomies. Post-mastectomy pain syndrome is thought to be linked with 
the damage of nerves in the chest and armpit after surgery. On the other hand, 
the main purpose of chemotherapy is to kill rapidly replicating malignant cells, 
however, it can also affect other highly dividing normal cells in human body. 
Gastrointestinal distresses such as nausea and vomiting are common in 
patients who had received chemotherapy. Also, these patients had suppressed 
immune system which might lead to viral infection such as herpes simplex 
virus (Elad et al., 2010). Moreover, paclitaxel was found to cause neuropathy 
in human body (Cliffer et al., 1998). Doxorubicin and trastuzumab have been 
shown to be associated with cardiotoxicity (Morris and Hudis, 2010) such as 
left ventricular dysfunction (Schmitz et al, 2012). Furthermore, tamoxifen has 
been reported to cause increased occurrence of deep vein thrombosis and 
possibly endometrial cancer (Brown, 2009). The combination of pertuzumab 
and trastuzumab was reported to cause cardiac toxicity in certain breast cancer 
patients (Portera et al., 2008). In addition to nausea and vomiting, 5-
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fluorouracil can also damage cognitive function in rare cases (Wigmore et al., 
2010). Furthermore, even though the external beam of radiation therapy is safe, 
some side effects might possibly occur such as fatigue, skin erythema and 
mild swelling, which could affect up to 100% patients (Whelan et al., 2000). 
Besides that, late side effects might possibly occur after radiation therapy, for 
example telangectasia and impaired cosmesis with fibrosis, as well as long 
term side effects such as arm lymphoedema and shoulder stiffness (Langlands 
et al., 2013). Nevertheless, patients who received hormone therapy commonly 
experienced hot flushes, painful joints and mood swings.  
In addition to drug toxicity, cancer treatment is also plagued by the 
development of drug resistance. For example, cancer cells can increase the 
expression of drug efflux pump (e.g. P-glycoprotein, breast cancer resistance 
protein (ABCG2)) to transport drug molecules out from the cells, thus 
preventing therapeutic actions (Szakács et al., 2004). Moreover, certain cancer 
cells were found to amplify survival pathway to overcome drug action, for 
example, PI3K/Akt pathway was amplified as a mechanism to overcome 
trastuzumab (Puglisi et al., 2012). Furthermore, the effect of lapatinib, such as 
inhibition of Akt pathway, could be reversed by derepression of FOXO3a 
which resulting in the increase of estrogen receptor transcription and estrogen 
receptor signaling (Guo and Sonenshein, 2004). Cancer stem cells can up-
regulate FOXO genes to increase the level of antioxidant enzymes, such as 
SOD (superoxide dismutase) and catalase, to maintain the redox status in the 
cells; hence, this will reduce the oxidative stress caused by radiation therapy 
and chemotherapy with redox-cycling agents (Tothova and Gilliland, 2007). 
Drug resistance was also found in the treatment of BRCA1/2 mutation cancers 
using platinum agents and PARP inhibitors. This might be due to the 
development of secondary or ‘reversion’ mutations that restored the activities 
of BRCA to certain degree (Maxwell and Domchek, 2012).    
Due to drug toxicity and drug resistance problems, there are increasing studies 
searching for potential drugs that can replace or complement conventional 
medicine for greater treatment efficacy. Natural products or traditional 
medicine serve as a large reserve pool for such purpose.  
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1.4 Thymoquinone: a potential anticancer drug from natural products 
Cancer is multi-factorial in origin and is affected by both genetic and 
environmental risk factors. The current trend of drug development is to 
develop a drug that can specifically target the signaling pathway that causes 
tumorigenesis. However, this kind of drug often leads to adverse effects and 
tumor resistance (Aggarwal et al., 2007). Thus, people start questioning 
whether this “one-target, one-drug approach” is capable to favorably solve the 
disease. Can a single-target drug treat a multi-factorial disease like cancer? It 
is well-known that drug combinations are more effective in treating complex 
diseases and are also less prone to acquired resistance (Keith et al., 2005). As 
such, it is possible that a compound that can target multiple signaling 
pathways is more effective because the disease system is less able to counter 
two or more interferences simultaneously (Aggarwal et al., 2007).  
Cancer is a complex disease arising from multiple alterations in DNA such as 
mutations, deletions and rearrangements. Thus, the assumption of “one drug 
for one target” may not adequate to address complex disease like cancer, 
which has deregulation of multiple signaling pathways and possible 
development of drug resistance (Fimognari et al., 2012). As compared to 
specific inhibitors, natural products generally target multiple signaling 
pathways which might be more effective in inhibiting tumor growth. Since 
natural products are derived mostly from edible vegetables, fruits and tea, they 
are likely to be safe as a source of pharmacological chemicals.  
48 of 65 drugs approved for cancer treatment over the period 1981-2002 were 
natural products or natural products-related (Newman et al., 2003). This 
suggests that natural products are great potential sources for new drug 
discovery. Numerous reports suggested that cancer signaling pathways could 
be inhibited by spice-derived nutraceuticals, for example capsaicinoids from 
red chili, curcumin from turmeric, and ursolic acid from rosemary (Sung, 
2012). A case-control study of gastric cancer in Italy reported that the 
increased intake of fresh vegetables, fresh fruits, spices and garlic could 
reduce the risk of this disease (Buiatti et al., 1989). Moreover, it has been 
suggested that the lower colon cancer incidence in India compared to most 
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Western countries could be attributed to the consumption of spice (Kaefer and 
Milner, 2008). Indeed, high consumption of dark yellow-orange or green 
vegetables and fruits was found to reduce the risk of breast cancer (Park et al., 
2008). A case-control study in Japan suggested that the consumption of 
soybean products, such as soy milk and tofu, could reduce the risk of breast 
cancer (OR=0.44) particularly in premenopausal women (Hirose et al., 2005). 
With extensive research, many natural products have great potential to be 
developed into anticancer agents.  
Thymoquinone (TQ) is a phytochemical found in the traditional Ayurvedic 
herb, Nigella sativa, which is native to South and Southwest Asia. TQ was 
first extracted in 1963 by El-Dakhakhany (El-Dakhakhany, 1963). Since its 
identification, TQ has been investigated extensively for its therapeutic effects 
in different types of disease such as cancer, inflammation, atherosclerosis, 
sepsis and diabetes (Woo et al., 2012). The results from a double-blind 
crossover clinical trial showed that TQ was able to produce antiepileptic effect 
in children with epilepsy (Akhondian et al., 2011). It was also found that the 
human body could tolerate a dose of TQ up to 2600 mg/day without any 
significant adverse effect (Al-Amri et al., 2009), suggesting the safe use of TQ 
in humans. 
 
                                           
Figure 1.2: Flower of Nigella sativa (left panel) and the molecular structure of 
thymoquinone (right panel). 




It was reported in many studies that TQ was able to suppress various types of 
cancer cells, including leukemia (HL-60 and Jurkat) (El-Mahdy et al., 2005; 
Alhosin et al., 2010), glioma/glioblastoma (U87 MG and T98G, M059K and 
M059J) (Cecarini et al., 2010; Gurung et al., 2010), pancreatic cancer (MIA 
PaCa-2, HPAC and BxPC-3) (Banerjee et al., 2009; Rooney et al., 2010), 
colorectal carcinoma (HT-29, HCT-116, DLD-1, Lovo and Caco-2) (Rooney 
et al., 2010; El Najjar et al., 2010), osteosarcoma (MG63 and MNNG/HOS) 
(Roepke et al., 2007) and prostate cancer (LNCaP, C4-2B, DU145 and PC-3) 
(Richards et al., 2006; Kaseb et al., 2007; Koka et al., 2010). In addition, the 
combination of TQ with conventional medicine produced greater cytotoxic 
effect, for example combined with cisplatin in NCI-H460 non-small cell lung 
cancer cells (Jafri et al., 2010), paclitaxel or doxorubicin in KBM-5 human 
myeloid cells (Sethi et al., 2008), and gemcitabine or oxaliplatin in HPAC 
human pancreatic cancer cells (Banerjee et al., 2009).  
The antitumor effects of TQ were also reported in animal models with 
different types of carcinoma. TQ was found to reduce the number and size of 
aberrant crypt foci in 1,2-dimethyl hydrazine-induced colon cancer in mice 
(Gali-Muhtasib et al., 2008b). Oral administration of TQ inhibited 
forestomach tumor incidence and multiplicity in benzo(a)pyrene-induced 
forestomach tumor mouse model (Badary et al., 1999). Moreover, TQ was 
found to inhibit the growth of various tumor xenograft models, including 
HCT-116 cell-induced colon tumor xenograft (Gali-Muhtasib et al., 2008b), 
C4-2B cell-induced prostate tumor xenograft (Kaseb et al., 2007), HPAC cell-
induced pancreatic tumor xenograft (Banerjee et al., 2009) and NCI-H460 
cell-induced lung tumor xenograft (Jafri et al., 2010).  
In addition, TQ showed potential inhibitory effects in cancer metastasis and 
angiogenesis. For example, TQ was found to inhibit human umbilical vein 
endothelial cell migration, invasion, and tube formation (Yi et al., 2008). TQ 
suppressed the migration of FG/COLO357 pancreatic cancer cells in a dose-
dependent manner (Torres et al., 2010), and inhibited the invasion of NCI-
H460 cells (Jafri et al., 2010). Moreover, TQ was found to significantly reduce 
the number of blood vessels in the tumors of PC-3 cell-induced prostate tumor 
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xenograft mouse model, indicating its inhibitory role in angiogenesis (Yi et al., 
2008).  
Taken together, TQ has promise as a potential anticancer agent. However, the 
anticancer effect of TQ in breast carcinoma was not well explained. As such, 
we were interested to investigate the detailed molecular mechanism(s) of 




Table 1.1: The anticancer effects of thymoquinone and its molecular 
targets.  
Anticancer effects Molecular Targets References 
Growth inhibition p53 
p73 
ROS 
Gali-Muhtasib et al. (2004a) 
Alhosin et al. (2010) 






Gali-Muhtasib et al. (2008a) 
Alhosin et al. (2010) 
Arafa et al. (2011) 
El-Najjar et al. (2010) 
Torres et al. (2010) 
Anti-inflammatory STAT-3 
NF-κB 
Li et al. (2010) 
Sethi et al. (2008) 
Anti-metastasis MMP-9 Sethi et al. (2008) 






1.5 Reactive oxygen species (ROS): role in tumorigenesis  
Reactive oxygen species (ROS) are oxygen-containing reactive molecules or 
ions, which are formed via incomplete one electron reduction of oxygen (Pan 
et al., 2009).  
 
 
Figure 1.3: Electron structure of common reactive oxygen species.   
Diagram adapted from http://www.biotek.com/resources/articles/reactive-oxygen-
species.html  
 
ROS can be generated from exogenous or endogenous sources of which some 
of them are carcinogenic (Cui, 2012). Mitochondria are significant sources of 
ROS due to their function as the power producer of a cell which consume 
oxygen molecules. ROS play important functions in cellular system including 
apoptosis, innate immunity, biosynthetic processes and cell signaling cascades 
(Rada and Leto, 2008; Brieger et al., 2012). Under normal physiological 
system, cells regulate the level of ROS by balancing ROS production and their 
scavenging system. However, the accumulation of ROS will damage proteins, 
lipids, membranes and even DNA. Some of the examples of DNA damage are 
single and double-stranded DNA breaks, DNA-protein crosslinks, 
depurination and depyrimidination (Barzilai and Yamamoto, 2004). Cellular 
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defense systems against ROS accumulation comprise of many detoxification 
enzymes including glutathione peroxidase, glutathione-S-transferase, catalase, 
superoxide dismutase and epoxide hydrolase (Acharya et al., 2010). Moreover, 
small molecules such as glutathione, ascorbic acid (vitamin C) and tocophenol 
(vitamin E) are also involved in cellular antioxidant processes. Excessive 
oxidative stress will lead to the development of human diseases such as 
neurodegenerative, metabolic and inflammatory diseases as well as cancer 
(Vurusaner et al., 2012).   
Increasing studies reported the idea of ROS which they play a double edge 
“sword” in carcinogenesis. The DNA damage caused by ROS can lead to the 
initiation and progression of carcinogenesis (Brieger et al., 2012). Gene 
mutations, particularly TP53, induced by ROS are mainly due to the 
modification of guanine, causing G to T transversion (Hollstein et al., 2001; 
Lunec et al., 2002). Low level of ROS promotes cancer cell growth partly due 
to its role as a mediator to Ras-induced cell cycle progression (Irani et al., 
1997). ROS were found to promote tumorigenesis by activating ERK1/2 via 
Ras, whereby ERK1/2 involved in survival pathways such as cell growth and 
apoptosis prevention (Abe et al., 2000; Aikawa et al., 1997). Oxidized DNA 
bases, such as 8-oxo-deoxyguanosine and thymine glycol, can lead to the 
initiation of oncogenes as well as the suppression of tumor suppressor genes 
(Kang, 2002). In addition, ROS were found to activate tumor promoting 
transcription factors such as NF-κB, AP-1, STAT3 and HIF-1α (Gupta et al., 
2012). NF-κB-regulated genes, such as Bcl-2, Bcl-xL and SOD, can promote 
tumor cell survival by inhibiting apoptosis. HIF-1α plays an important role in 
tumor angiogenesis by stimulating blood vessel formation. It was reported that 
the progression of human breast cancer to metastatic state was correlated to 
hydroxyl radical-induced DNA damage (Malins et al., 1996). Chronic hepatitis 
infections by Hepatitis B and Hepatitis C viruses increased oxidative stress 
(activation of NF-κB and STAT3) in liver tissues promoting hepatocellular 
carcinoma (Waris and Siddiqui, 2003).  
With low to modest levels of ROS promote tumor cell proliferation and 
metastasis, high level of ROS can suppress tumor growth by activating 
apoptosis (Gupta et al., 2012). Both extrinsic and intrinsic pathways of 
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apoptosis involve ROS (Ozben, 2007). ROS was shown to activate p38 
MAPK for apoptotic cell death in human cervical cancer cells (Kang and Lee, 
2008). Moreover, p38α can be activated via p53-mediated ROS production, 
whereby this p53/ROS/p38α cascade involved in cisplatin-induced apoptosis 
in HCT116 colorectal cancer cells (Bragado et al., 2007). Furthermore, p53 
was found to increase cellular ROS level for cell death mechanism by 
initiating the transcription of pro-oxidant genes such as PIG3 and PIG6 
(Polyak et al., 1997). High level of ROS suppressed tumor growth by 
activating cell cycle inhibitor such as LATS1 (Large tumor suppressor kinase 
1) (Takahashi et al., 2006). Interestingly, Dolado et al. suggested that ROS 
promote tumorigenesis, and p38 MAPK-induced apoptosis is initiated in 
response to ROS accumulation; this response plays an important role in 
inhibiting tumor initiation during oxidative stress (Dolado et al., 2007). 
Exogenous administration of hydrogen peroxide activated caspase 3 for 
apoptotic cell death in lymphoma cells (Hampton and Orrenius, 1997). 
Bortezomib, a selective inhibitor of the proteasome, suppressed gastric cancer 
cells by NF-κB inhibition, as well as ROS induction and JNK activation 
(Nakata et al., 2011). Moreover, increased level of hydrogen peroxide by 
piperlongumine treatment was able to suppress various types of tumor 
xenograft mouse model, with no apparent toxicity in normal mice (Raj et al., 
2011). Thus, agents that can modulate ROS level have the potential to 
suppress cancer cells.  
There are numerous natural products that can modulate cellular redox status to 
inhibit cancer cell growth, for example curcumin (Sandur et al., 2007), 
gambogic acid (Nie et al., 2009) and promegranate extract (Weisburg et al., 
2010). Beta-sitosterol, a type of phytosterols, was found to induce apoptosis in 
U266 multiple myeloma cells through ROS-mediated AMPK and JNK 
activations (Sook et al., 2013). Hirsutanol A, a compound isolated from the 
fungus, Chondrostereum sp., inhibited SW620 human colon cancer cells via 
mitochondrial-independent ROS production (Yang et al., 2013). In contrast, 
genistein, an isoflavone found in soybean enriched foods, was able to protect 
cells from oxidative stress by acting as a ROS scavenger. Also, this compound 
is a strong inhibitor of NF-κB, Akt and PTK signaling pathways (Banerjee et 
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al., 2008). Indole-3-carbinol, a phytochemical found in vegetables, was found 
to induce BRCA1 for cell protection against oxidative stress from hydrogen 
peroxide and γ-radiation (Fan et al., 2009). Moreover, garlic extract was able 
to inhibit the oxidative modification of lipids from 7,12-
dimethylbenz(a)anthracene (Das and Saha, 2009). 
It has been shown in several reports that TQ was able to induce ROS 
production as a mechanism to kill cancer cells (Woo et al., 2012). TQ showed 
anti-oxidative activity at lower concentration (Mansour et al., 2002), but acted 
as a pro-oxidant at higher concentration (El-Najjar et al., 2010; Koka et al., 
2010). It was reported that TQ induced ROS production for apoptotic cell 
death and Akt inhibition in primary effusion lymphoma cells (Hussain et al., 
2011). Pre-treatment with N-acetylcysteine, a strong antioxidant, could reverse 
TQ-induced apoptosis in primary effusion lymphoma cells (Hussain et al., 
2011), DLD-1 human colon cancer cells (El-Najjar et al., 2010) and C4-2B 
prostate cancer cells (Koka et al., 2010).  
The effect of TQ on ROS production in breast cancer cells was not explained. 
Therefore, we were interested in investigating the role that ROS might play in 
the anticancer effects of TQ. The relationship of ROS with PPAR-γ and p38 in 
the action of TQ were also examined in this study.  
 
 
1.6 Peroxisome proliferator-activated receptor gamma (PPAR-γ): role 
 in cancer suppression  
PPARs are nuclear receptor that have three main isoforms namely PPAR-α, 
PPAR-β/δ and PPAR-γ. They are ligand-activated transcription factors, 
whereby upon binding to agonist will increase the rate of transcription 
initiation (Berger and Moller, 2002). Once binding to ligand, PPAR-γ will 
hetero-dimerize with retinoid X receptor, whereby this complex moves into 
nucleus to bind to PPRE (Peroxisome Proliferators Response Element) 
sequence in the regulated promoter region to initiate transcription. PPARs play 
a critical role in lipid metabolism, and many of the natural fatty acids are 
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ligands to these receptors. For example, linoleic acid and arachidonic acid was 
found to bind to PPAR-α in micromolar range (Göttlicher et al., 1992). 
Palmitic acid and its analogue, 2-bromopalmitic acid, are known as PPAR-β/δ 
agonists (Amri et al., 1995). PPAR-γ regulates fatty acid storage and glucose 
metabolism, and it was shown that adipose-specific PPAR-γ knockout mice 
failed to develop adipose tissue after fed with high fat diet (Jones et al., 2005).  
Thiazolidinedione is a class of medicine used for type 2 diabetes. Its members, 
including rosiglitazone, pioglitazone and ciglitazone, can bind to PPAR-γ for 
gene transcription to regulate adipocyte differentiation, lipid and glucose 
metabolism, and energy homeostasis (Berger and Moller, 2002). However, 
increasing studies reported that PPAR-γ might play an important role in cell 
proliferation, differentiation and apoptosis (Sertznig et al., 2007). Through 
non-genomic targets, PPAR-γ was shown to inhibit β-catenin pathway, 
STAT3/NF-κB signaling and androgen receptor (Robbins and Nie, 2012). 
PPAR-γ showed positive correlation to patients’ survivor in breast cancer 
(Jiang et al., 2009), but opposite fashion in pancreatic cancer (Giaginis et al., 
2009). Moreover, transgenic mice with lung-specific PPAR-γ over-expression 
showed reduced tumor formation after ethyl carbamate induction (Nemenoff 
et al., 2008). The administration of diet rich in conjugated linoleic acid (a 
PPAR-γ ligand) was able to protect against tumor formation in azoxymethane-
induced mice (Evans et al., 2010). 
Ligand activation of PPAR-γ was able to induce apoptosis in breast cancer 
(Kumar et al., 2009) and non-small cell lung cancer cells (Chang et al., 2000). 
Moreover, the invasion and metastasis of breast cancer cells could be inhibited 
by ligand activation of PPAR-γ (Liu et al., 2003; Panigrahy et al., 2002). It has 
been shown that PPAR-γ was able to induce G1/S arrest by up-regulating 
p21WAF1/Cip1 (Chang et al., 2000) or p27Kip1 (Motomura et al., 2000), and 
down-regulating cyclin D1 (Yin et al., 2001). In addition, PPAR-γ activation 
by PPAR-γ ligands, 15d-PGJ2 and troglitazone, was able to suppress MCF-7 
and MDA-MB-231 cell growth possibly by inhibition of cell cycle progression 
(Clay et al., 1999). Moreover, PPAR-γ activation by 15d-PGJ2 suppressed 
gastric cancer cells by G1 cell cycle arrest, and this inhibitory effect was 
greater when combined with 9-cis retinoic acid, a ligand of RXRα (Sato et al., 
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2000).  It was shown that troglitazone-induced apoptosis in NCI-H23 human 
non-small lung cancer cells was mediated via PPAR-γ and ERK1/2, whereby 
the knock-down of PPAR-γ and treatment of EKR1/2-specific inhibitor were 
able to prevent troglitazone-induced apoptosis (Li et al., 2006). In addition, 
activation of PPAR-γ was found to inhibit hepatocellular carcinoma 
metastases both in vitro and in vivo (Shen et al., 2012).  
Synergism was observed in the combination of rosiglitazone and platinum-
based drugs in the treatment of several types of cancer, whereby this could be 
due to the PPAR-γ-mediated down-regulation of metallothioneins, a protein 
responsible for resistance in platinum-based therapy (Girnun et al., 2007). This 
is further explained by another study showing that rosiglitazone combined 
with cisplatin for enhanced anticancer effects in 7,12-
dimethylbenz(a)anthracene-induced breast cancer rats, and this combination 
could also reduce the nephrotoxicity induced by cisplatin (Tikoo et al., 2009). 
Combined treatment of troglitazone and TRAIL synergistically induced 
apoptosis in DLD-1 human colon cancer cells through DR5 (Death Receptor-5) 
up-regulation (Koyama et al., 2014).    
However, there are studies revealed the contradiction for the inhibitory role of 
PPAR-γ activation in tumorigenesis. For example, 15d-PGJ2 was found to up-
regulate VEGF via heme oxygenase-1 and ERK1/2 in MCF-7 cells (Kim et al., 
2006). Moreover, there are studies reported that the anticancer activities of 
PPAR-γ ligands might be mediated via PPAR-γ-independent pathway. For 
example, troglitazone suppressed KU812 leukemia cells with undetectable 
level of PPAR-γ mRNA (Abe et al., 2002). This is further explained by 
another study showing that delta2-troglitazone, which devoid of PPAR-γ 
agonist activity, was able to suppress MCF-7 and MDA-MB-231 breast cancer 
cells (Colin et al., 2010). In addition, the cytotoxicity of 15d-PGJ2 in 786-O, 
Caki-2 and ACHN human renal cancer cell lines was mediated in caspase-
dependent and PPAR-γ-independent manners (Fujita et al., 2012). Moreover, 
troglitazone-induced cytotoxicity in 786-O, Caki-2 and ACHN human renal 
cancer cells was mediated via a PPAR-γ-independent pathway and p38 MAPK 
pathway (Fujita et al., 2011). It was suggested that the PPAR-γ-independent 
effects of PPAR-γ ligands could be due to the binding of these ligands to other 
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proteins such as p50 (Kulkarni et al., 2012). Thus, these effects did not require 
PPAR-γ-dependent transcriptional activation and could occur even PPAR-γ is 
functionally inactivated or deleted. 
It was reported that many anticancer natural products could modulate PPAR-γ 
activity for anticancer action. For example, white tea extract induced apoptosis 
in A549 and H520 non-small cell lung cancer cells by up-regulating PPAR-γ 
activity (Mao et al., 2010). In addition, bitter gourd seed oil was able to induce 
apoptosis in Caco-2 colon cancer cells by up-regulating PPAR-γ, GADD45 
and p53 (Yasui et al., 2005). Thus, agents that can modulate PPAR-γ could be 
potential drugs for cancer treatment, and natural products serve as a huge 
source for this purpose. There was no study reporting the effect of TQ on the 
PPAR-γ pathway in breast cancer cells. Therefore, we were interested to 
examine the role that PPAR-γ might play in TQ’s anticancer activities.   
 
 
1.7 The p38 MAPK pathway: role in tumor suppression  
In order to survive and perform physiological functions, cells respond to a 
number of extracellular stimuli such as hormones, mitogens and biological 
ligands, follow by conversion of these signals into a wide range of 
intracellular responses. MAPKs (Mitogen-activated protein kinases) are 
protein Ser/Thr kinases that can initiate signaling cascades in response to 
extracellular stimuli, and this is often mediated through the activation of 
transcription factors. Nearly all eukaryotic cells utilize multiple MAPK 
pathways to regulate a number of cellular functions including gene expression, 
mitosis, metabolism, survival and apoptosis (Cargnello and Roux, 2011). By 
far, three most extensively studied groups of MAPKs are the extracellular 
signal-regulated kinases 1/2 (ERK1/2), c-Jun amino (N)-terminal kinases 1/2/3 
(JNK1/2/3) and p38 isoforms (α, β, γ and δ). Usually, ERK1/2 is involved in 
cell proliferation and differentiation, while JNK and p38 cascades are 
activated by cellular stresses. However, depending on cell lines and types of 
stimulation, these cascades may response differently and even opposing 
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function (Keshet and Seger, 2010). Under rare condition, ERK1/2 may play a 
role in response to stress and apoptosis (Bacus et al., 2001); while JNK can 
mediate cell proliferation in certain conditions. Deregulation of these cascades 
often leads to diseases such as diabetes (Zick, 2005) and cancer (Dhillon et al., 
2007). 
In general, p38 isoform in mammals is activated by environmental stresses and 
inflammatory cytokines. These extracellular stimuli will activate MAPKKKs, 
which in turn, phosphorylate MKK3 and MKK6, the upstream protein kinases 
of p38. Activation of p38 is achieved by dual phosphorylation at the Thr-Gly-
Tyr motif (New and Han, 1998). The p38 pathway plays a number of roles 
including regulation of apoptosis, cell cycle progression, growth and 
differentiation. Upon activation, p38 phosphorylates a number of proteins 
including Bax, Bcl-2, p53, ATF1/2/6 and MSK1/2 (Cuadrado and Nebreda, 
2010). A number of diseases have been found to associate with p38 signaling, 
such as rheumatoid arthritis (Pargellis and Regan, 2003), cardiovascular 
disease (Behr et al., 2003) and Parkinson’s disease (Wilms et al., 2003).  
Many studies demonstrated that p38 pathway plays an important role in cancer 
therapy as a tumor suppressor gene. Molnar et al. reported that p38 could up-
regulate p16 expression, which in turn, inhibiting cyclin D1/cdk4 activity 
(Molnar et al., 1997). p38 was shown to induce G1/S arrest by activating p53, 
which in turn, increased the level of p21 (Kim et al., 2002). Moreover, p38-
mediated G2/M checkpoint could be initiated in response to DNA double 
strand breaks (Thornton and Rincon, 2009). It was shown that p38 could 
stabilize HBP1 protein by phosphorylating it (Xiu et al., 2003), whereby 
stabilized HBP1 could negatively regulate cell cycle genes such as N-myc and 
cyclin D1 (Sampson et al., 2001; Tevosian et al., 1997). In addition of cell 
cycle regulation, p38 also plays a role in apoptosis. p38 was found to increase 
the level of a new protein called p18 (Hamlet), of which p18 could interact 
with p53 for the transcription of pro-apoptotic genes such as Puma and Noxa 
(Cuadrado et al., 2007). It was shown that several chemotherapeutic agents, 
such as nocodazole, taxol, vincristine and vinblastine, required p38 activation 
for apoptotic cell death (Deacon et al., 2003). This was further explained by 
SB203580 and SB202190, whereby these p38-specific inhibitors were found 
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to reverse nocodazole-induced apoptosis (Deacon et al., 2003). Imatinib 
mesylate treatment (a specific inhibitor of BCR-ABL tyrosine kinase) was 
found to activate p38 pathway, whereby the treatment of p38-specific inhibitor 
could abrogate the anti-leukemic effects of imatinib mesylate in primary 
leukemic progenitors originated from patients with chronic myelogenous 
leukemia (Parmar et al., 2004). Inhibition of p38 was reported to be associated 
with the resistance to anoikis, thus allowing the circulating cancer cells to 
survive (Cheng et al., 2004). Interestingly, p38 could be activated by 
oncogenic stresses, whereas this activation involved in Ras-induced 
senescence in mouse embryo fibroblasts (Bulavin et al., 2003). Moreover, p-
p38 was nearly undetectable in most solid tumors including lung, breast, 
gastric, liver, renal and ovarian cancers, while this protein was relatively 
higher expressed in normal organs (Liao and Hung, 2003).  
In contrast to its antitumor activities, p38 was also found to play an important 
role in inflammation and cancer metastasis (Koul et al., 2013). The expression 
of several cytokines, such as IL-1, IL-6, IL-8 and TNF-α, is regulated by p38 
pathway (Song et al., 2006). Moreover, p38 was found to regulate the 
induction of pro-inflammatory mediator cyclooxygenase 2 (COX-2) which 
involved in breast cancer progression (Timoshenko et al., 2006). The 
expression of MMP (matrix metalloproteinase) family enzymes, including 
MMP-1, MMP-2, MMP-9 and MMP-13, is regulated by p38 pathway (Song et 
al., 2006). Moreover, p38 was found to be involved in H-Ras-induced cell 
motility and invasive phenotype of MCF-10A human breast epithelial cells 
(Kim et al., 2003).   
There are many natural products that modulate p38 pathway to produce 
anticancer activities. It was shown that platycodin D, a triterpenoid saponin 
isolated from the root of Platycodon grandiflorum, induced p38 activation for 
apoptosis in AGS human gastric cancer cells (Chun et al., 2013). In addition, 
acanthoic acid from Acanthopanax koreanum was able to induce growth 
inhibition and apoptosis in HL-60 leukemia cells, whereby these effects could 
be blocked by pre-treatment with SB203580 (Kim et al., 2012b). Moreover, 
neferine, a major alkaloid component in lotus embryos, was found to induce 
G1 arrest in human osteosarcoma cells through p38-mediated p21 stabilization 
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(Zhang et al., 2012). Pre-treatment with SB203580 could abrogate neferine-
induced p21 up-regulation (Zhang et al., 2012).  
There are few numbers of paper reported the effect of TQ on MAPKs pathway. 
TQ was found to increase the phosphorylation status of ERK and JNK, but not 
p38, in DLD-1 colon cancer cells (El-Najjar et al., 2010). Interestingly, the 
increased phosphorylation of ERK and JNK were found to protect against TQ-
induced apoptosis, whereby pre-treatment with ERK (PD98059) and JNK 
(SP600125) specific inhibitors could sensitize the cells to the cytotoxicity of 
TQ (El-Najjar et al., 2010). On the other hand, TQ was shown to increase the 
activation of JNK and p38 in FG/COLO357 pancreatic cancer cells by down-
regulating mucin-4 (Torres et al., 2010). Other than these studies, the role of 
p38 pathway in TQ’s anticancer activities was not well explained. Thus, we 
aimed to study the effect of TQ on p38 pathway in breast cancer cells. The 
relationship of p38 with ROS and PPAR-γ in the effects of TQ was also 








1.8 Objectives and overview of study 
1.8.1 Objectives of study 
Despite numerous studies reporting the anticancer activities of TQ, the effect 
of TQ on breast carcinoma and its molecular mechanism(s) of action were still 
not well explained. Hence, we were interested to investigate the anticancer 
effects of TQ in breast carcinoma through in vitro and in vivo experiments, 
and also to elucidate the mechanism(s) of action of this compound via 
different assays.  
Our first aim was to investigate the inhibitory effect of TQ in breast cancer 
cells by examining growth inhibition and apoptosis. The apoptotic pathway 
involved in TQ treatment was studied through the investigation on several 
apoptotic proteins. The effect of TQ on breast cancer cell migration and 
invasion was also examined. On the basis of evidence from our collaborator 
lab, we found that TQ was able to bind to PPAR-γ through interaction with 
several residues in the receptor (Woo et al., 2011). Therefore, we expanded 
our interest on PPAR-γ by investigating its role in TQ’s anticancer effects. 
Next, we were interested to examine whether ROS would be the upstream 
regulator of PPAR-γ. We also investigated the role of ROS in TQ-induced 
apoptosis in breast cancer cells. ROS has been shown to regulate p38 MAPK 
for anticancer action of certain agents (Bragado et al., 2007; Kang and Lee, 
2008); hence, we were interested to know whether this relationship was also 
involved in the mechanism of action of TQ. We studied the relationship 
between ROS and p38, and also, p38 and PPAR-γ. How p38 plays its role in 
TQ’s anticancer effects was also one of our objectives. The later phase of the 
study was to translate in vitro data to in vivo by performing experiments on 
breast tumor xenograft mouse model. The protein expression of several genes 
of interest in the tumor tissues was examined and these findings were 
compared with those from cell line studies. The antitumor effect of the 
combination of TQ with doxorubicin, a chemotherapeutic agent, was also 
compared to the effect of either agent alone. We also measured the antioxidant 
enzymes/molecules in mouse liver tissues in an attempt to study the 
relationship between ROS and TQ.  
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These experiments would support our hypothesis that TQ is a potential 
anticancer agent that is able to suppress breast carcinoma through multiple 
signaling pathways, including ROS, PPAR-γ and p38 MAPK.     
 
1.8.2 Overview of study 
The mechanism of action of TQ was first investigated in breast cancer cells. 
MTT assay was used to examine the effect of TQ on cell viability. Several 
breast cancer cell lines (MCF-7, MDA-MB-231 and BT-474) were exposed to 
increasing concentrations of TQ for different incubation periods. This was to 
investigate the dose- and time-response effects of TQ on cell viability. In 
addition, the cytotoxicity of the combination of TQ and chemotherapeutic 
agents was also examined with MTT assay. This experiment was to investigate 
whether these combinations would produce synergistic or enhanced cytotoxic 
effect compared to either agent alone. The effect of TQ on cell cycle 
progression was examined by flow cytometry after propidium iodide staining, 
as well as the protein expression of cell cycle genes (such as cyclin D1 and 
cyclin E) by Western blot. The purpose was to investigate whether TQ would 
cause cell cycle arrest in breast cancer cells. Flow cytometry (annexin V 
staining) and Western blot (PARP cleavage) were used to examine the pro-
apoptotic effect of TQ in breast cancer cells. Moreover, the protein expression 
of caspases and Bcl-2 family genes, such as Bcl-xL, Bcl-2 and Bax, were 
examined by Western blot. This was to study the effect of TQ on the apoptotic 
pathway.  
‘Wound-healing’ assay was used to study the effect of TQ on breast cancer 
cell migration, whereby the ability of TQ-treated cells to fill the ‘wound’ area 
was evaluated. The effect of TQ on breast cancer cell invasion was studied 
with commercial invasion assay kit. The purpose of these experiments was to 
investigate the anti-metastatic effect of TQ in breast cancer cells. 
According to the data from our collaborator, TQ was found to form interaction 
with several residues of PPAR-γ molecule (Woo et al., 2011). Therefore, 
whether PPAR-γ involved in the anticancer activities of TQ in breast cancer 
28 
 
cells was also investigated. Luciferase assay was used to measure the activity 
of various PPARs in TQ-treated cells. If there is any induction in PPARs after 
TQ treatment, a respective specific inhibitor would be used to determine the 
specificity of this induction. After determining that TQ was able to induce 
PPAR-γ specifically, our next objective was to study its effect on the PPAR-γ 
pathway in greater detail. Dose- and time-response effects of TQ on PPAR-γ 
activity were examined by luciferase assay. Whether PPAR-γ activation 
involved in TQ-induced apoptosis was examined with PPAR-γ-specific 
inhibitor in TQ-treated cells. Real time RT-PCR and Western blot were used 
to examine the mRNA and protein expression, respectively, of PPAR-γ-
regulated genes in TQ-treated cells with or without PPAR-γ-specific inhibitor. 
This was to study whether PPAR-γ activation was involved in the suppression 
of these genes induced by TQ. In addition to PPAR-γ-specific inhibitor, a 
genetic approach, i.e. PPAR-γ dominant negative, was also used to study the 
role of PPAR-γ activation in the mechanism of action of TQ. This genetic 
approach was to over-express faulty PPAR-γ receptor, which in turn, resulting 
in reduced PPAR-γ activation. The mRNA and protein expression of PPAR-γ-
regulated genes in TQ-treated cells were examined with or without PPAR-γ 
dominant negative transfection.  
Our next phase of study was to determine whether ROS involved in the 
anticancer activities of TQ. The level of ROS in TQ-treated cells was 
measured with flow cytometry after Mitosox staining. After determining that 
TQ was able to induce ROS production in breast cancer cells, NAC, a strong 
antioxidant, was used to study the role of ROS in TQ’s anticancer effects. 
NAC was used in TQ-treated cells to study whether it would make any 
significant difference to TQ’s growth inhibition and pro-apoptotic effects. 
Moreover, whether ROS induction involved in the suppression of anti-
apoptotic genes induced by TQ was also examined by using NAC in TQ-
treated cells.  
Next, the effect of TQ on p38 activation was investigated. Western blot and 
p38 ELISA kit were used to examine the expression level of p-p38/p38 in TQ-
treated cells. Following this, p38-specific inhibitor, SB203580, was used in 
TQ-treated cells to study whether the growth inhibition and pro-apoptotic 
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effects of TQ required p38 activation. Moreover, the possible role of TQ-
induced p38 activation in the suppression of anti-apoptotic genes was also 
investigated with p38-specific inhibitor. In addition to pharmacological 
inhibitor, a genetic approach, i.e. p38 siRNA gene silencing, was also used to 
study the role of p38 activation in TQ-induced apoptosis.    
In addition of evaluating the role of PPAR-γ, ROS and p38 MAPK in the 
anticancer activities of TQ, our next interest was to study the possible 
interaction between these pathways. Whether the use of PPAR-γ-specific 
inhibitor would affect the level of TQ-induced ROS and TQ-induced p38 
activation was examined. Similarly, whether the use of NAC would affect the 
level of TQ-induced PPAR-γ expression and TQ-induced p38 activation was 
also investigated. A p38-specific inhibitor was also used to determine whether 
p38 activation was involved in TQ-induced PPAR-γ expression and TQ-
induced ROS production. 
After determining the anticancer activities of TQ and its possible mechanisms 
of action in breast cancer cells, our next interest was to examine these effects 
in an animal model. Breast tumor xenograft mouse model was used to study 
the antitumor effects of TQ and its combination with a chemotherapeutic drug. 
Breast cancer cells were injected subcutaneously to the right flank region of 
female nude mice to develop breast tumor xenograft. When the size of tumors 
was about 100 mm3, treatments were started for a total of two weeks. Tumor 
size and body weight were measured twice per week. After euthanisation of 
the mice, tumor tissues were collected for histological, immunohistochemical 
and Western blot analysis. Apoptosis marker (DNA fragmentation) and cell 
proliferation marker (Ki67) of tumor tissues were examined by TUNEL 
staining and immunohistochemistry, respectively. The protein expression of 
genes of interest (such as p-p38/p38, PPAR-γ and various anti-apoptotic genes) 
in the tumor tissues were examined by Western blot. These data would be 
compared to the in vitro findings. Mouse liver tissues were also collected for 
enzymatic assays to measure the level of several antioxidant 
enzymes/molecules, which aimed to study the pro-oxidant/anti-oxidant effect 
of TQ.   
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2 MATERIALS AND METHODS 
2.1 Chemicals and antibodies 
Trypsin EDTA, trypan blue, thiazoyl blue tetrazolium bromide (MTT), 
propidium iodide, RNase, insulin, hydrocortisone, thymoquinone and N-
acetylcysteine were purchased from Sigma-Aldrich (St. Louis, MO, USA), 
while doxorubicin was purchased from Euroasian Chemical Private Ltd. 
(Mumbai, India). SB203580 was purchased from Promega (WI, USA). 15d-
PGJ2 and GW9662 were purchased from Cayman (Michigan, USA). 
GSK0660 and GW0742 were purchased from Tocris Bioscience (Ellisville, 
MO, USA). RPMI1640, DMEM, DMEM/F12, Opti-MEM and fetal bovine 
serum were purchased from Hyclone (Loughborough, UK). Antibiotic-
antimycotic mixture was purchased from Gemini Bio-products (West 
Sacramento, CA, USA). Dimethyl sulfoxide was purchased from MP 
Biomedicals (Solon, OH, USA). BD matrigel was purchased from BD 
Biosciences (Franklin Lakes, NJ, USA). Antibodies to Bcl-2, Bcl-xL, PPAR-γ, 
cyclin D1, cyclin E, p53, p21, p27, caspase 7, Ki67, XIAP, JNK, p-JNK, ERK, 
p-ERK and PARP were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA), while caspase 8, caspase 9, survivin, p38, p-p38 and β-actin 
were purchased from Cell Signaling (Beverly, MA, USA). Chicken anti-rabbit 
IgG HRP-conjugated, chicken anti-mouse IgG HRP-conjugated, chicken anti-
rabbit IgG TR-conjugated antibodies, p38 siRNA and control siRNA-A were 
purchased from Santa Cruz Biotechnology. 
 
2.2  Cell lines 
MCF-7, MDA-MB-231 and BT-474 breast cancer cell lines as well as MCF-
10A normal breast epithelial cell line were purchased from ATCC (Manassas, 
VA, USA). MCF-7 and MDA-MB-231 cells were cultured in RPMI1640 
medium supplemented with 10% fetal bovine serum and 1% antibiotic-
antimycotic. BT-474 cells were cultured in DMEM medium supplemented 
with 12.5% FBS and 1% antibiotics-antimycotic. MCF-10A cells were 
cultured in DMEM/F12 medium supplemented with 5% FBS, 1% antibiotics-
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antimycotic, 10 μg/ml insulin, 20 ng/ml EGF and 0.5 μg/ml hydrocortisone. 
All cell culture were maintained at 37 ºC and 5% CO2 in a humidified 
atmosphere. 
 
2.3  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT) assay 
The cytotoxic effect of TQ was assessed by MTT assay. The principal of this 
assay is that live cells can reduce the yellow dye, MTT, to purple formazan 
crystals for quantification. Briefly, breast cancer cells were seeded (104 
cells/well) in a 96-well microtiter plate followed by overnight incubation. 
After appropriate treatment, 10 µl MTT solution (5 mg/ml) was added into 
each well for 4 h. The mixture was then removed carefully via pipette, and the 
remaining formazan crystals formed were dissolved with 100 µl DMSO. The 
absorbance of each well was read after 30 mins at 570 nm by a microplate 
reader (Tecan Infinite M200, Mannedorf, Switzerland).    
 
2.4  Cell cycle analysis 
Cell cycle progression of breast cancer cells was examined by flow cytometry 
after propidium iodide (PI) staining. Cell cycle phase can be differentiated by 
measuring their DNA content, where G1 phase is 2n, S phase is between 2n 
and 4n, and G2 phase is 4n. PI can diffuse into cell nucleus and binds to DNA 
proportionately to its amount; thus, by measuring PI signal, the DNA content 
of each cell can be determined. Briefly, cells were seeded (1.5 X 105 cells/well) 
in a 6-well microtiter plate followed by overnight incubation. The cells were 
synchronized by starvation in serum-free medium for 24 h. After appropriate 
treatment, the cells were detached and fixed with 70% ethanol for at least 2 h 
before staining with PI solution (mixed with RNase) under dark condition for 
20 mins. The cells were then analyzed with a flow cytometer (CyAnTM ADP 




2.5  Annexin V assay  
The level of apoptosis of cancer cells was assessed with Annexin V-PI kit 
from Miltenyi Biotec (Bergisch Gladbach, Germany). Annexin V can 
specifically bind to phosphatidylserine. Cells undergoing apoptosis will 
experience diffusion of phosphatidylserine from inner cell membrane to outer 
cell membrane, whereby these proteins can be quantified by targeting them 
with fluorescence-tagged Annexin V. The experimental procedures were 
carried out according to the manufacturer’s protocol. Briefly, cells were 
seeded (2.6 X 105 cells/well) in a 6-well microtiter plate followed by overnight 
incubation. After appropriate treatment, the cells were trypsinized, washed, 
and incubated with Annexin V-FITC solution for 15 mins under dark 
condition. After a washing step, the cells were analyzed with a flow cytometer 
(CyAnTM ADP from Beckman Coulter, Brea, CA, USA) immediately after 
adding of PI solution.  
 
2.6  Western blot analysis  
The protein expression of genes of interest in breast cancer cells and tumor 
tissues were measured by Western blot. The principal behind of this technique 
is to transfer proteins from an acrylamide-gel to a membrane, which they can 
be specifically targeted by antibodies of interest. These antibodies are tagged 
with enzyme to cleave substrate for chemiluminescence signal. The 
chemiluminescence signal, which is proportionately to the quantity of 
antibody, is measured by exposing substrate-added membrane to X-ray film or 
Gel-Doc machine. Briefly, cells were seeded (2.6 X 105 cells/well) in a 6-well 
microtiter plate followed by overnight incubation. After appropriate treatment, 
the cells were trypsinized followed by whole cell lysate extraction (cell lysis 
buffer: 5 M NaCl, 1 M HEPES, 0.1 M EGTA, 0.5 M EDTA, 1 % Triton-X). 
For in vivo study, the tumor tissues were homogenized for tissue lysate 
extraction (tissue lysis buffer: 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 0.1 % Triton X, 0.1 % SDS, 2.5 mM sodium pyrophosphate, 1 
mM beta-glycerophosphate, 1 mM Na3VO4). Both cell lysate and tissue lysate 
were centrifuged at 13,000 rpm and the resulting supernatants were collected. 
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After protein estimation with Bio-Rad protein assay (Hercules, CA, USA), a 
calculated volume of lysate was mixed with laemmli sample buffer, whereby 
the mixture was resolved by 10% or 12% SDS/PAGE gel and then 
electroblotted onto a nitrocellulose membrane. The membrane was blocked 
with 5% fat-free milk for 1 h before washed with TBST buffer. The membrane 
was probed with primary antibody for overnight at 4ºC, and then washed and 
probed with HRP-conjugated secondary antibody for 1 h at room temperature. 
The membrane was examined for its chemiluminescence signal by ECL 
analysis system (GE Healthcare, Little Chalfont, Buckinghamshire, UK). 
Densitometric analysis of Western blot bands was performed with Image J 
software. Band intensity was expressed as percentage relative to untreated 
control after normalization to β-actin.   
 
2.7  Cell migration assay 
The “wound-healing” assay was used to investigate the migration of cancer 
cells after appropriate treatment. The principal behind is to create a “wound” 
or long strip within cell culture, which follow by the examination for the 
ability of cells to grow into the “wound” area. Briefly, cells were seeded in a 
6-well microtiter plate and incubated until about 80-90% confluence. A 
‘wound’ was created using pipette tip and rinsed with PBS to remove detached 
cells. Media with appropriate treatment was added for 48 h incubation. The 
observation of the cells was recorded at 0, 24 and 48 h with a fluorescence 
microscope (Olympus BX51, Shinjuku, Japan).  
 
2.8  Invasion assay 
The invasiveness of breast cancer cells were examined with BD MatrigelTM 
Invasion Chamber 24-well Plate 8 µm (BD Biosciences, San Diego, MA, 
USA). The idea is to seed breast cancer cells at one side of matrigel chamber 
follow by the introduction of chemo-attractant at the opposite side. The 
invasiveness of cancer cells was investigated by examining the number of 
cells that had migrated through matrigel toward the chemo-attractant. Briefly, 
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the chambers supplied by the manufacturer were allowed to rehydrate in 
serum-free media for 2 h before being placed in a 24-well microtiter plate 
filled with 5% FBS media. A total of 6 X 104 breast cancer cells were 
resuspended in serum-free media before added into the chamber. The cells 
were allowed to settle for 4–6 h inside the chamber before exposure to 
appropriate concentrations of TQ for 24 h or 48 h. The media was removed 
carefully and the chamber was transferred into a well filled with 4% 
paraformaldehyde for cell fixation. After 30 mins incubation, the migratory 
cells, which attached at the bottom of the chamber, were stained with 0.5% 
crystal violet solution for 15 mins. The chamber was then washed with 
deionized water for 5 mins. The observation of the stained migratory cells was 
recorded with a fluorescence microscope (Olympus BX51, Shinjuku, Japan). 
The number of the migratory cells after TQ treatment was normalized against 
untreated group. 
 
2.9  Luciferase assay 
The activity of PPARs was investigated by two-step luciferase assay as 
described previously (Ramachandran et al., 2012). GAL4 sequence is 
incorporated into the PPAR promoter region. GAL4-luc is incorporated into 
DNA to produce GAL4 binding domain to regulate luciferase signal. Upon 
binding of agonist, PPAR proteins will move into the nucleus and bind to 
peroxisome proliferator response elements (PPRE) to initiate transcription. 
GAL4 protein will be produced and this protein will then bind to GAL4 
binding domain inducing luciferase signal. Briefly, cells were seeded (6 X 104 
cells/well) in a 12-well microtiter plate followed by overnight incubation. The 
cells were incubated in DMEM medium for 1 h before plasmid transfection. 
The cells were transfected with GAL4-PPAR-α LBD, GAL4-PPAR-γ LBD or 
GAL4-PPAR-β/δ LBD plasmid (were kindly provided by Dr. Javier F. 
Piedrafita, Torrey Pines Institute for Molecular Studies, San Diego, CA, USA), 











Figure 2.2 Schematic diagram for one-step luciferase assay.  
 
For dominant negative experiment, one-step luciferase assay was used (Kumar 
et al., 2008). The main idea is to fuse pPPRE-tk-luc (three PPREs from rat 
acyl-CoA oxidase promoter under the control of the Herpes simplex virus 
thymidine kinase promoter) to DNA, whereby upon binding of PPAR-γ, 
induces luciferase signal. Briefly, cells were seeded (6 X 104 cells/well) in a 
12-well microtiter plate followed by overnight incubation. The cells were 
incubated in DMEM medium for 1 h before plasmid transfection. The cells 
were transfected with PPAR-γDN (PPARγC126A/E127A containing amino 
acid substitutions in the DNA binding domain that abolish binding to PPAR-γ 
response elements) or pCMX-mPPARγ plasmid (a cDNA clone encoding the 
mouse PPARγ), together with pPPRE-tk-Luc and Renilla plasmid as an 
internal control. PPAR-γDN was a generous gift by Dr. Christopher K. Glass 
(UCSD, San Diego, CA, USA) while pCMX-mPPARγ was kindly provided 





For both two step and one step luciferase assays, the cells were transfected 
with calcium phosphate transfection kit (Clontech, Mountain View, CA, USA) 
for 12–14 h before recovery with normal RPMI1640 medium for at least 6 h. 
After appropriate treatment, the cells were harvested using ice-cold reporter 
lysis buffer. The lysate was then centrifuged at 12,000 rpm for 3 mins. The 
supernatant was mixed with luciferase substrate solution (Promega, WI, USA) 
for luciferase reading, followed by Stops & Glow buffer (Promega, WI, USA) 
for Renilla reading. Bioluminescence generated was measured using Sirius 
luminometer v3.1 (Berthold, Munich, Germany). The luciferase reading 
obtained was normalized to the corresponding Renilla reading and to the 
protein amount. 
 
2.10  Real time RT-PCR (reverse transcription-polymerase chain 
 reaction) 
The mRNA expression of genes of interest was examined by real time RT-
PCR. The total mRNA will first be converted to cDNA by reverse 
transcription. Next, fluorescence-tagged primer probe will be used to 
specifically bind to gene of interest to allow gene amplification through 
polymerase chain reaction. Thus, the fluorescence level will represent the level 
of mRNA of gene of interest. Briefly, cells were seeded (2 X 105 cells/well) in 
a 6-well microtiter plate followed by overnight incubation. After appropriate 
treatment, total cellular RNAs were isolated using Trizol reagent (Invitrogen, 
Carlsbad, CA, USA). TaqMan ○R  Reverse Transcription kit (Applied 
Biosystems, Foster City, CA, USA) was used for reverse transcription reaction 
of mRNA to cDNA. 1 µg of total RNA was mixed with reaction mixture (RT 
buffer, MgCl2, dNTPs, random hexamers, RNase inhibitors, RTase and H2O) 
to make a total volume of 10 ml. The reverse transcription reaction was carried 
out over a PCR thermal cycle (25 ºC for 10 mins, 37 ºC for 60 mins and 95 ºC 
for 5 mins). The resulting cDNA solution was then mixed with TaqMan○R  
Universal Master Mix 2.0 (Applied Biosystems, Foster City, CA, USA) 
together with target primer probes (purchased as kits from Applied 
Biosystems). The polymerase chain reaction was carried out with ABI Prism 
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7500 (Applied Biosystems, Foster City, CA, USA). All reactions were carried 
out in duplicate and the mRNA expression was normalized against 18S rRNA 
as an internal control. 
 
2.11 Mitosox assay 
The level of ROS was examined with Mitosox assay (Invitrogen, Carlsbad, 
CA, USA). Breast cancer cells were seeded (2.6 X 105 cells/well) in a 6-well 
microtiter plate followed by overnight incubation. After appropriate treatment, 
the cells were trypsinized, washed and incubated with Mitosox-added serum 
free medium at 37ºC for 15 mins under dark condition. The cells were then 
analyzed with a flow cytometer (BD LSRII, Franklin Lakes, NJ, USA).  
 
2.12  PathScan® Phospho-p38 MAPK (Thr180/Tyr182) Sandwich 
 ELISA Kit 
The p-p38 protein level of cancer cells was measured with PathScan® 
Phospho-p38 MAPK (Thr180/Tyr182) Sandwich ELISA Kit (Cell Signaling, 
Beverly, MA, USA). Incubation of cell lysate in the supplied plate will allow 
the p-p38 protein to be captured by coated antibody. The captured p-p38 
protein is then targeted by p-p38 specific antibody follow by HRP-secondary 
antibody. Finally, the HRP enzyme on the secondary antibody will cleave 
substrate for color signal. The experimental procedures were carried out 
according to the manufacturer’s protocol. Briefly, cells were seeded (2.6 X 105 
cells/well) in a 6-well microtiter plate followed by overnight incubation. After 
appropriate treatment, lysis buffer (Cell Signaling, Beverly, MA, USA) was 
added for whole cell extraction. The cell lysate was subjected to centrifugation 
at 13,000 rpm. The resulting supernatant was added into the wells supplied by 
the manufacturer. After 4 h incubation at 37ºC, the wells were washed with 
wash buffer for 4 times. p38 MAPK rabbit detection antibody was then added 
for 1 h at 37ºC. The washing step was repeated, followed by 30 mins 
incubation with HRP-linked secondary antibody at 37ºC. The washing step 
was again repeated, followed by 10 mins incubation with TMB substrate at 
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37ºC. STOP solution was then added into each well for 5 mins. The 
absorbance was read at 450 nm with a microplate reader (Tecan Infinite M200, 
Mannedorf, Switzerland). 
 
2.13  Gene silencing with siRNA 
The expression of gene of interest can be suppressed using siRNA gene 
silencing. The mRNAs of gene of interest are bind by specific siRNA with 
complementary nucleotide sequence creating double-stranded RNA which will 
then be degraded by endo- and exo-nucleases.  Briefly, cells were seeded (1.7 
X 105 cells/well) in a 6-well microtiter plate followed by overnight incubation. 
The cells were tranfected with 30 nM of p38 siRNA or control siRNA-A using 
Oligofectamine tranfection reagent (Invitrogen, Carlsbad, CA, USA) for 6 h 
according to the manufacturer’s protocol. The cells were let to recover in 
serum-added medium for at least 24 h before exposure to appropriate 
treatment. 
 
2.14  Breast tumor xenograft mouse model 
Female nude mice (BALB/c OlaHsd-foxn1) were purchased from Biological 
Resource Centre Biopolis (Singapore). The animal protocol used in this 
experiment was approved by The NUS Institutional Animal Care and Use 
Committee (protocol no. 065/11). Upon arrival, all nude mice were kept in 
individual disposable cages with ventilation, and given food and water ad lib. 
All mice were acclimatisated for at least 7 days before used. Breast cancer 
cells were sent for infection check before used in this experiment. After 
trypsinized, the cells were washed with serum-free medium twice before 
resuspended in matrigel-added serum-free medium. Each mouse was injected 
subcutaneously with 107 MDA-MB-231 human breast cancer cells at the right 
flank region. The tumor was allowed to grow until about 100 mm3 (Volume = 
½ X width2 X length) before introducing any treatment. The mice were 




Table 2.1: Treatment protocol of tumor-induced mice 
Groups Treatments Times per week 
Vehicle  Saline water (i.p.) 6 
4 mg/kg TQ 4 mg/kg TQ (i.p.) 6 
8 mg/kg TQ 8 mg/kg TQ (i.p.) 6 
2.5 mg/kg Dox 2.5 mg/kg Dox (i.p.) 1 
Combined 4 mg/kg TQ (i.p.) + 2.5 mg/kg Dox (i.p.) 6 + 1 
 
The tumor volume (measured by Vernier caliper) and body weight were 
measured twice per week. All mice were euthanized with CO2 asphyxiation 
after two weeks of treatment. Tumor tissues were collected for histological, 
immunohistochemical and Western blot analysis, while liver tissues were 
collected for enzymatic assays. 
 
2.15  Hematoxylin and Eosin (H&E) staining 
H&E staining was used to study the tissue structure of mouse tumors. This 
method can stain nucleus to purple color and cytoplasm to pink color. Briefly, 
the tumor tissues were placed in 10% neutral buffered formalin solution 
(Sigma-Aldrich, St. Louis, MO, USA) for at least 1 day before being 
processed and paraffinized. The sample tissues were sectioned at 4 µm thick. 
Next, the tissue section was deparaffinized with Histo-Clear (National 
Diagnostics, Atlanta, GA, USA) for 5 mins. The tissue section was rehydrated 
with decreasing concentrations of ethanol, i.e. 100% ethanol, 95% ethanol, 80% 
ethanol and 70% ethanol. The tissue section was then rinsed with running 
water for 5 mins before stained with Hematoxylin (Merck, Germany) for 8 
mins. Next, the tissue section was rinsed with acid alcohol for 3 seconds 
followed by running water for 2 mins. The tissue section was then rinsed with 
weak ammonia for 10 seconds followed by running water for 10 mins. In the 
following step, the tissue section was stained with Eosin (Merck, Germany) 
for 5 mins. The tissue section was then dehydrated with increasing 
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concentrations of ethanol, i.e. 70% ethanol, 80% ethanol, 95% ethanol and 100% 
ethanol. Next, the tissue section was rinsed with Histo-Clear for 3 mins before 
covered with a cover slip using mounting medium. The tissue section was 
examined and photographed with a fluorescence microscope (Olympus BX51, 
Shinjuku, Japan).  
 
2.16  TUNEL staining 
The level of apoptosis of tumor tissues was examined with TUNEL staining 
(Promega, WI, USA). This method can detect DNA fragmentation which is a 
characteristic hallmark of apoptosis. Fragmented DNA exposes 3’ OH ends 
which can be targeted by terminal deoxynucleotidyl transferase (TdT), follow 
by incorporation of fluorescence-tagged dUTP. The experimental procedures 
were carried out according to the manufacturer’s protocol. Briefly, the tissue 
section was deparaffinized with Histo-Clear (National Diagnostics, Atlanta, 
GA, USA) before rehydration with decreasing concentrations of ethanol. After 
washing with 0.85% NaCl and PBS, the tissue section was fixed with 4% 
formaldehyde for 15 mins. After another PBS wash, the tissue section was 
covered with Proteinase K solution for 8-10 mins. Following another PBS 
wash, the tissue section was again fixed with 4% formaldehyde for 5 mins. 
After PBS wash, the tissue section was covered with equilibrium buffer for 5-
10 mins before addition of TdT reaction mixture for 1 h incubation under dark 
condition. Next, the tissue section was incubated with SSC solution for 15 
mins, followed by a final PBS wash. The tissue section was counterstained 
with DAPI (Sigma-Aldrich, St. Louis, MO, USA) for 5 mins. Immediately 
after drying, the tissue section was examined and photographed with a 
fluorescence microscope (Olympus BX51, Shinjuku, Japan). The graph 
showed the average number of TUNEL-positive cells from three photographs 






2.17  Ki67 immunohistochemistry 
Ki67 protein is a cellular marker for proliferation. By using Ki67 antibody, 
this protein can be specifically targeted and be quantified through fluorescence 
signal on secondary antibody. Firstly, the tissue section was deparaffinized 
with Histo-Clear (National Diagnostics, Atlanta, GA, USA) before undergoing 
antigen retrieval step with citrate buffer. The tissue section was next blocked 
with 2% fetal bovine serum for 20-30 mins. The tissue section was then 
incubated with rabbit anti-Ki67 antibody for 1 h at room temperature. After 
PBS wash, the tissue section was incubated with chicken anti-rabbit IgG TR-
conjugated antibody for 1 h under dark condition. The tissue section was then 
counterstained with DAPI (Sigma-Aldrich, St. Louis, MO, USA) for 5 mins. 
Immediately after drying, the tissue section was examined and photographed 
with a fluorescence microscope (Olympus BX51, Shinjuku, Japan). The graph 
showed the average number of Ki67-positive cells from three photographs in 
each treatment group. 
 
2.18  Catalase assay  
Catalase is an antioxidant enzyme that catalyzes the conversion of hydrogen 
peroxide to oxygen and water. The catalase level in mouse liver tissues was 
measured by using catalase assay kit from Cayman Chemical (Ann Arbor, 
Michigan, USA). The experimental procedures were carried out according to 
the manufacturer’s protocol. Briefly, the liver tissues were homogenized in 
cold buffer (50 mM potassium phosphate, 1 mM EDTA, pH 7). The 
supernatant was collected after 10 mins centrifugation at 10,000 g. The sample 
was mixed to diluted assay buffer and methanol in a 96-well microtiter plate. 
The reaction was initiated by adding diluted hydrogen peroxide for 20 mins 
with constant shaking. Diluted potassium hydroxide and catalase purpald were 
then added followed by 10 mins incubation with constant shaking. Next, 
catalase potassium periodate was added for 5 mins incubation with constant 
shaking. The absorbance was then read at 540 nm with a microplate reader 
(Tecan Infinite M200, Mannedorf, Switzerland). 
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2.19  Superoxide dismutase (SOD) assay  
SOD is an antioxidant enzyme which catalyzes the conversion of superoxide 
to oxygen and hydrogen peroxide. The SOD level in mouse liver tissues was 
measured using the SOD assay kit from Cayman Chemical (Ann Arbor, 
Michigan, USA). The experimental procedures were carried out according to 
the manufacturer’s protocol. Briefly, the liver tissues were homogenized in 
HEPES buffer (20 mM HEPES buffer, 1 mM EGTA, 210 mM mannitol, 70 
mM sucrose, pH 7.2). The supernatant was collected after 5 mins 
centrifugation at 1,500 g. The sample was mixed to diluted radical detector in 
a 96-well microtiter plate. The reaction was initiated by adding diluted 
xanthine oxidase for 20 mins with constant shaking. The absorbance was then 
read at 450 nm with a microplate reader (Tecan infinite M200, Mannedorf, 
Switzerland). 
 
2.20  Glutathione assay  
Glutathione is a tripeptide which serves as a reducing agent. The thiol group 
can donate electron to unstable molecules (e.g. reactive oxygen species) thus 
resulting in the conversion of glutathione to glutathione disulfide. The 
glutathione level in mouse liver tissues was measured using the glutathione 
assay kit from Cayman Chemical (Ann Arbor, Michigan, USA). The 
experimental procedures were carried out according to the manufacturer’s 
protocol. Briefly, the liver tissues were homogenized in cold buffer (50 mM 
phosphate, 1 mM EDTA, pH 6-7). The supernatant was collected after 10 
mins centrifugation at 10,000 g. The sample was first deproteinated by mixing 
with triethanolamine. The sample mixture was then mixed to assay cocktail in 
a 96-well microtiter plate and incubated immediately for 25 mins under dark 
condition with constant shaking. The absorbance was then read at 405 nm with 





2.21  Statistical analysis 
Statistical analysis was performed by one way analysis of variance (ANOVA) 
and Student’s t test. Tukey’s t test was used after one way ANOVA to 
determine the significance between the groups. A p-value of less than 0.05 
was considered to be statistically significant.  
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3  RESULTS 
3.1  Studies on the cytotoxic effects of TQ in breast cancer cells 
3.1.1  Growth inhibition effect of TQ  
TQ was first examined for its growth inhibition effect in several breast cancer 
cell lines (MCF-7, MDA-MB-231 and BT-474) and a normal breast cell line 
(MCF-10A) by using MTT assay. As shown in Figure 3.1.1, TQ induced 
potent growth inhibition effect in all tested cell lines in a dose- and time-
dependent manner. The IC50 values of TQ in MCF-7 cells after 12 h, 24 h and 
48 h exposures were 48, 40 and 32 μM, respectively. In MDA-MB-231 cells, 
the IC50 values of TQ after 12 h, 24 h and 48 h exposures were 24, 14 and 11 
μM, respectively. On the other hand, the IC50 values of TQ after 12 h, 24 h and 
48 h exposures in BT-474 cells were 38, 18 and 21 μM, respectively. The IC50 
values of TQ in MCF-10A cells after 12 h, 24 h and 48 h exposure were 46, 30 
and 32 μM, respectively. From the results, the sensitivity of MCF-10A cells to 
the cytotoxicity of TQ was comparable to MCF-7 cells, however, this normal 
breast cell line was less sensitive when compared to MDA-MB-231 and BT-
474 cell lines. Overall, the IC50 values of TQ were less than 50 μM suggesting 
the strong potency of this drug in inhibiting the growth of breast cancer cells.  
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Figure 3.1.1 The dose- and time-response curves of TQ treatment in several 
breast cancer cell lines and a normal breast cell line.  
Cells were treated with increasing concentrations of TQ for 12 h, 24 h and 48 h 
before analyzed with MTT assay. Values are means ± S.E.M. of at least three 
independent experiments. 
 
Table 3.1: IC50 values of TQ in different breast cell lines after 12 h, 24 h 
and 48 h exposures  
Cell lines 12 h (μM) 24 h (μM) 48 h (μM) 
MCF-7 48 40 32 
MDA-MB-231 24 14 11 
BT-474 38 18 21 





3.1.2  Effect of the combination of TQ and chemotherapeutic drugs  
The effect of the combination of TQ and chemotherapeutic drugs on breast 
cancer cell growth was investigated with MTT assay. MCF-7 cells were 
treated with TQ alone or in combination with doxorubicin, 5-fluorouracil or 
paclitaxel. Our results showed that the combination of TQ with doxorubicin or 
5-fluorouracil could produce enhanced growth inhibition effect than either 
agent alone (Figure 3.1.2). A low dose of TQ (20 μM) was found to increase 
the cytotoxicity of doxorubicin by 2.6 fold and 5-fluorouracil by 2.7 fold. 
However, the combination of TQ and paclitaxel did not produce significant 
difference in growth inhibition than either agent alone (Figure 3.1.2). Together, 
these findings demonstrate the possible use of TQ as a complement agent in 
combination therapy.  
 
 
Figure 3.1.2 Growth inhibition rate of the combination of TQ and 
chemotherapeutic drugs.  
MCF-7 cells were treated with 20 µM TQ with or without the indicated dose of 
chemotherapeutic drugs for 24 h before analyzed with MTT assay. Values are means 
± S.E.M. of at least three independent experiments. * p<0.05 vs. control.  
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3.1.3  Effect of TQ on cell cycle progression 
Flow cytometry analysis was used to study the chronology of the cellular and 
molecular events of TQ-treated MCF-7 cells. After TQ treatment, the cells 
were stained with propidium iodide before analyzed with flow cytometry. As 
shown in Figure 3.1.3A, no cell cycle arrest was observed after TQ treatment, 
however, subG1 accumulation was observed at 80 μM TQ after 24 h exposure, 
and at 60 μM and 80 μM TQ after 48 h exposure. SubG1 phase represents 
genetic material less than 2n which indicates nuclear fragmentation, a 
characteristic of apoptosis. In addition, the protein expression of cell cycle 
genes was also investigated with Western blot. Our results showed that TQ 
treatment did not cause significant change in the protein expression of cyclin 






      
 
Figure 3.1.3 Effect of TQ on cell cycle progression and cell cycle genes.  
(A) Effect of TQ on cell cycle progression. MCF-7 cells were treated with increasing 
concentrations of TQ for 12 h, 24 h and 48 h before analysis with flow cytometry. 
The data are representative of three independent experiments. (B) Effect of TQ on the 
protein expression of cell cycle genes. MCF-7 cells were treated with increasing 
concentrations of TQ for 12 h. Whole cell lysate was then used for Western blot 








3.1.4  Pro-apoptotic effect of TQ  
Upon apoptosis, phosphatidylserine proteins, which are normally in the inner 
cell membrane, will be exposed to the cell surface. These phospholipid 
components have a high affinity for protein molecule like annexin V. Thus, by 
labeling annexin V with fluorescein, the cell population with exposed 
phosphatidylserine can be detected for apoptosis measurement. Our data 
showed that TQ increased the percentage of annexin V-positive cells in a 
dose-dependent manner (Figure 3.1.4A). Interestingly, TQ treatment appeared 
to increase the percentage of annexin V-positive cells at the upper right 
quadrant (known as late apoptosis) than the lower right quadrant (known as 
early apoptosis). In addition to annexin V assay, PARP protein cleavage was 
also used to examine apoptosis. Poly (ADP-ribose) polymerase (PARP) is a 
family of protein that is involved in many cellular processes such as DNA 
repair and cell death. Its inactivation through caspase-dependent cleavage 
indicates apoptosis induction. As shown in Figure 3.1.4B, TQ treatment was 
found to induce the cleavage of PARP protein in a dose-dependent manner. 
Together, these results suggested that TQ was able to induce apoptosis in 
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Figure 3.1.4 Effect of TQ on apoptosis induction.  
(A) Effect of TQ on annexin V positive cell population. MCF-7 cells were treated 
with increasing concentrations of TQ for 12 h before analyzed with annexin V assay. 
The data are representative of three independent experiments. (B) Effect of TQ on the 
protein expression of cleaved-PARP/PARP. MCF-7 cells were treated with increasing 
concentrations of TQ for 12 h. Whole cell lysate was then used for Western blot 
analysis. The data are representative of at least three independent experiments. * 




3.1.5  Effect of TQ on apoptotic pathway 
After having determined that TQ is pro-apoptotic, our next interest was to 
study the effect of TQ on various caspases and Bcl-2 family proteins. TQ was 
found to reduce the protein expression of procaspase 8, 9 and 7 in a dose-
dependent manner (Figure 3.1.5), suggested that cleavage events were 
occurred. Moreover, the protein expression of Bcl-2 was decreased after TQ 
treatment, with a slight increase in Bax. This would resulting in an increase of 
Bax/Bcl-2 ratio (Figure 3.1.5). These results explained the pro-apoptotic effect 
















Figure 3.1.5 Effect of TQ on the protein expression of caspases and Bcl-2 family 
proteins.  
MCF-7 cells were treated with increasing concentrations of TQ for 12 h. Whole cell 
lysate was then used for Western blot analysis. The data are representative of at least 





3.2  Studies on the anti-metastatic effect of TQ in breast cancer cells 
3.2.1  Effect of TQ on cell migration 
In order to study the effect of TQ on breast cancer cell migration, ‘wound 
healing’ assay was used. A ‘wound’ was created within cell culture and the 
ability of breast cancer cells to fill up the ‘wound’ after TQ treatment was 
examined. At 48 h microscopic observation, the ‘wound’ was barely detected 
in PBS-treated cells in both MCF-7 and MDA-MB-231 cell lines. In contrast, 
TQ was found to inhibit the migration of cancer cells from both cell lines to 
the created ‘wound’, as shown by the visible ‘wound’ in the cell culture after 
24 h and 48 h TQ exposure (Figure 3.2.1).  
        





        
Figure 3.2.1 Effect of TQ on breast cancer cell migration.  
(A) MCF-7 and (B) MDA-MB-231 cells were cultured until 80-90% confluent before 
a ‘wound’ was created. The cells were treated with indicated concentrations of TQ for 
48 h. Microscopy observations were recorded at 0 h, 24 h and 48 h after TQ treatment. 




 3.2.2  Effect of TQ on cell invasion 
The invasiveness of breast cancer cells after TQ treatment was examined with 
a commercial invasion assay kit (BD MatrigelTM Invasion Chamber 24-well 
Plate 8 micron). As shown in Figure 3.2.2, TQ reduced the number of stained 
cells in a dose-dependent manner in MDA-MB-231 cells but not MCF-7 cells. 
This could be due to the strong invasive property of MDA-MB-231 cells but 
low to medium in MCF-7 cells.  
 
 






          
Figure 3.2.2 Effect of TQ on breast cancer cell invasion.  
BD MatrigelTM Invasion Chamber 24-well plate 8 micron from BD Biosciences was 
used according to the manufacturer’s protocol. Indicated concentrations of TQ were 
added into the chamber for 48 h in (A) MCF-7 cells or 24 h in (B) MDA-MB-231 
cells. The number of the migratory cells of TQ-treated groups was normalized against 
the untreated group. Values are means ± S.E.M. of two or three independent 




3.3  Studies on the role of PPAR-γ in the anticancer activities of TQ 
3.3.1  Effect of TQ on the activity of PPARs 
Since TQ was found to form interaction with several residues of PPAR-γ 
molecule (Woo et al., 2011), thus whether the effects of TQ involved PPARs 
were investigated. The effect of TQ on the activity of PPARs was first tested 
by using two-step luciferase assay as described in Materials and Methods. As 
shown in Figure 3.3.1A, TQ significantly increased the activity of PPAR-γ and 
PPAR-β/δ in MCF-7 cells. Although the activity of PPAR-α was increased 
after TQ treatment, however this increase was not significant. Next, whether 
these inductions were specific were examined by using respective 
pharmacological agonist and antagonist. The activity of PPAR-γ was found to 
both be induced by TQ and PPAR-γ agonist, 15d-PGJ2, as shown in Figure 
3.3.1B. These inductions could then be reversed by pre-treatment with PPAR-
γ antagonist, GW9662 (Figure 3.3.1B). Similarly, the activity of PPAR-β/δ 
could both be induced by TQ and PPAR-β/δ agonist, GW0742 (Figure 3.3.1C). 
Pre-treatment with PPAR-β/δ antagonist, GSK0660, could reverse GW0742-
induced PPAR-β/δ activity but not TQ-induced PPAR-β/δ activity.  
 
         A 





Figure 3.3.1 Effect of TQ on various PPARs.  
Two step luciferase assay was used whereby MCF-7 cells were transfected with 
either of GAL4-PPAR-α LBD, GAL4-PPAR-γ LBD or GAL4-PPAR-β/δ LBD 
plasmids, together with GAL4-Luc and Renilla plasmids for 12-14 h before 
appropriate treatment. (A) Effect of TQ on the activity of various PPARs. Transfected 
cells were treated with 40 µM TQ for 18 h. Whole cell lysate was then used for 
luciferase assay. The data are expressed as percentages in relative to the control. 
Values are means ± S.E.M. of two or three independent experiments. * p<0.05, ** 
p<0.01 vs. control. (B) Study on the specificity of TQ on PPAR-γ activity. 
Transfected cells were pre-treated with 10 µM or 20 µM GW9662 for 2 h before 
treatment with 40 µM TQ or 20 µM 15d-PGJ2 for 18 h. Whole cell lysate was then 
used for luciferase assay. The data are expressed as percentages in relative to the 
control. Values are means ± S.E.M. of two or three independent experiments. * 
p<0.05. (C) Study on the specificity of TQ on PPAR-β/δ activity. Transfected cells 
were pre-treated with 50 µM GSK0660 for 4 h before treatment with 40 µM TQ or 10 
µM GW0742 for 18 h. Whole cell lysate was then used for luciferase assay. The data 
are expressed as percentages in relative to the control. Values are means ± S.E.M. of 
two or three independent experiments. * p<0.05.  
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3.3.2  Effect of TQ on PPAR-γ activity  
Since the effect of TQ on PPAR-γ activity was specific, our next interest was 
to study the effect of TQ on PPAR-γ pathway in a greater detail. One-step 
luciferase assay was used to measure PPAR-γ activity as described in 
Materials and Methods section. As shown in Figure 3.3.2, TQ induced PPAR-
γ activity in a dose- and time-dependent manner in MCF-7 cells. TQ at 40 μM 




Figure 3.3.2 The dose- and time-response effects of TQ on PPAR-γ activity.  
One step luciferase assay was used whereby MCF-7 cells were transfected with 
pPPRE-tk-Luc and Renilla plasmids for 12-14 h before treatment with increasing 
concentrations of TQ for 6, 8 and 18 h. Whole cell lysate was then used for luciferase 
assay. The data are expressed as percentages in relative to the control. Values are 





3.3.3  Effect of TQ on the expression of PPAR-γ and PPAR-γ-regulated 
genes 
Genes such as Bcl-2, Bcl-xL, cyclin D1 and survivin are important in cell 
cycle progression and apoptotic pathway. Since these genes were found to be 
modulated by PPAR-γ pathway (Robbins and Nie, 2012), the expression of 
these genes after TQ treatment was also examined. From the results, the 
mRNA expression of PPAR-γ in MCF-7 cells was significantly increased at 2 
h TQ exposure but gradually decreased till insignificant at 8 h exposure 
(Figure 3.3.3A). The mRNA expression of PPAR-γ-regulated genes, such as 
Bcl-2, Bcl-xL and survivin, in MCF-7 cells was significantly decreased in a 
time-dependent manner after TQ treatment; however no significant change 
was observed in cyclin D1 (Figure 3.3.3A). Similarly, the protein expression 
of PPAR-γ in MCF-7 cells was significantly increased after TQ treatment 
(Figure 3.3.3B). Interestingly, a decreasing trend was observed in MDA-MB-
231 cells after TQ treatment (Figure 3.3.3B). The protein expression of PPAR-
γ-regulated genes including Bcl-2, Bcl-xL and survivin, but not cyclin D1, was 
decreased after TQ treatment in MCF-7 cells, in line with the mRNA results 

























   
 
Figure 3.3.3 Effect of TQ on the expression of PPAR-γ and PPAR-γ-regulated 
genes.  
(A) Effect of TQ on the mRNA expression of PPAR-γ and PPAR-γ-regulated genes 
in MCF-7 cells. Cells were treated with 40 µM TQ for 0, 2, 4 and 8 h. The cells were 
then harvested for real time RT-PCR. Values are means ± S.E.M. of two or three 
independent experiments. * p<0.05, ** p<0.01, *** p<0.001 vs. negative control. (B) 
Effect of TQ on the protein expression of PPAR-γ in MCF-7 and MDA-MB-231 cells. 
MCF-7 and MDA-MB-231 cells were treated with 40 µM TQ for 0, 4, 8 and 12 h. 
Whole cell lysate was then used for Western blot analysis. The data are representative 
of at least three independent experiments. * p<0.05, ** p<0.01 vs. negative control. 
(C) Effect of TQ on the protein expression of PPAR-γ-regulated genes in MCF-7 
cells. Cells were treated with 40 µM TQ for 0, 4, 8, 12 and 24 h. Whole cell lysate 
was then used for Western blot analysis. The data are representative of at least three 
independent experiments. * p<0.05, ** p<0.01, *** p<0.001 vs. negative control.  
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3.3.4  Effect of GW9662 on TQ-induced apoptosis and TQ-induced 
suppression of PPAR-γ-regulated genes 
A PPAR-γ inhibitor, GW9662, was used to examine whether it could reverse 
TQ-induced PPAR-γ activation. GW9662 can covalently bind to Cys285 
located on helix 3 of the PPAR-γ ligand binding domain resulting in the 
irreversible loss of ligand binding (Leesnitzer et al., 2002). By using one-step 
luciferase assay, pre-treatment with GW9662 was found to significantly 
reverse TQ-induced PPAR-γ activity in MCF-7 cells (Figure 3.3.4A). This 
reversal, however, was not able to restore PPAR-γ activity to the basal level. 
In addition, GW9662 could also reverse TQ-induced apoptosis, at least 
partially, as shown in Figure 3.3.4B. Next, whether the change in PPAR-γ 
activity would affect the mRNA and protein expressions of PPAR-γ-regulated 
genes in TQ-treated cells were also investigated. Our data showed that the 
decrease of survivin mRNA expression, but not Bcl-2 and Bcl-xL, induced by 
TQ could be reversed by GW9662 (Figure 3.3.4C). Similarly, GW9662 was 
found to reverse the decrease of survivin protein expression induced by TQ, 
but not Bcl-2 and Bcl-xL (Figure 3.3.4D), which was in line with their mRNA 
results. These results suggested that the suppression of survivin could be due 
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Figure 3.3.4 Effect of GW9662 on the apoptotic effect of TQ and the expression 
of PPAR-γ-regulated genes after TQ treatment.  
(A) Effect of GW9662 on TQ-induced PPAR-γ activity in MCF-7 cells. One-step 
luciferase assay was used whereby cells were transfected with pPPRE-tk-Luc and 
Renilla plasmids for 12-14 h. The cells were pre-treated with 10 µM GW9662 for 2 h 
before treatment with 40 µM TQ for 6 and 18 h. Whole cell lysate was then used for 
luciferase assay. The data are expressed as percentages in relative to the control. 
Values are means ± S.E.M. of two or three independent experiments. * p<0.05. (B) 
Effect of GW9662 on TQ-induced apoptosis in MCF-7 cells. Cells were pre-treated 
with 10 or 20 µM GW9662 for 2 h before treatment with 50 µM TQ for 12 h. The 
cells were then analyzed with annexin V assay. Values are means ± S.E.M. of three 
independent experiments. * p<0.05. (C) Effect of GW9662 on the mRNA expression 
of PPAR-γ and PPAR-γ-regulated genes after TQ treatment. MCF-7 cells were pre-
treated with 10 µM GW9662 for 2 h before treatment with 40 µM TQ for 8 h. The 
cells were then harvested for real time RT-PCR. The data are expressed as the 
percentage relative to their respective control. Values are means ± S.E.M. of two or 
three independent experiments. * p<0.05. (D) Effect of GW9662 on the protein 
expression of PPAR-γ-regulated genes after TQ treatment. MCF-7 cells were pre-
treated with 10 µM GW9662 for 2 h before treatment with 40 µM TQ for 24 h. 
Whole cell lysate was then used for Western blot analysis. The data are representative 




3.3.5  Effect of PPAR-γ dominant negative on TQ-induced suppression 
of PPAR-γ-regulated genes 
In addition to pharmacological approach (PPAR-γ inhibitor), a genetic 
approach, i.e. PPAR-γ dominant negative, was also used to suppress PPAR-γ 
activity which aimed to investigate the role of TQ-induced PPAR-γ activation 
on TQ’s effects. The increase of PPAR-γ protein expression (Figure 3.3.5C) 
confirmed the successful transfection of PPAR-γ dominant negative (PPAR-
γC126A/E127A) plasmids, whereby this increase represented the over-expression 
of faulty PPAR-γ receptor (Kumar et al., 2009; Kumar et al., 2013). This type 
of faulty receptor would bind to PPAR-γ ligands but would not initiate 
downstream signaling. As shown in Figure 3.3.5A by one-step luciferase assay, 
PPAR-γ dominant negative significantly reversed TQ-induced PPAR-γ 
activity in MCF-7 cells, though this reversal was not completely. A small 
reduction in PPAR-γ activity was observed in vehicle-control cells after 
PPAR-γ dominant negative transfection, suggesting that the antagonism effect 
on wild type PPAR-γ was not completely. By using real time RT-PCR, PPAR-
γ dominant negative was found to reverse the decrease of survivin mRNA 
expression induced by TQ, but not Bcl-2 and Bcl-xL (Figure 3.3.5B). 
Similarly, the decrease of survivin protein expression induced by TQ could 
also be reversed by PPAR-γ dominant negative, but not Bcl-2 and Bcl-xL 
(Figure 3.3.5C). These trends were similar to those in the results of PPAR-γ 
inhibitor, suggesting that the suppression of survivin was indeed due to TQ-
induced PPAR-γ activation.  
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Figure 3.3.5 Effect of PPAR-γ dominant negative on the expression of PPAR-γ-
regulated genes after TQ treatment.  
(A) Effect of PPAR-γ dominant negative on TQ-induced PPAR-γ activity. One step 
luciferase assay was used whereby MCF-7 cells were transfected with PPAR-γDN or 
pCMX plasmids, together with pPPRE-tk-Luc and Renilla plasmids for 12-14 h 
before treatment with 40 µM TQ for 18 h. Whole cell lysate was then used for 
luciferase assay. The data are expressed as percentages in relative to the control.  
Values are means ± S.E.M. of two or three independent experiments. * p<0.05. (B) 
Effect of PPAR-γ dominant negative on the mRNA expression of PPAR-γ-regulated 
genes after TQ treatment. MCF-7 cells were transfected with PPAR-γDN or pCMX 
plasmids for 12-14 h before treatment with 40 µM of TQ for 8 h. The cells were then 
harvested for real time RT-PCR. The data are expressed as the percentages relative to 
their respective control. Values are means ± S.E.M. of two or three independent 
experiments. * p<0.05. (C) Effect of PPAR-γ dominant negative on the protein 
expression of PPAR-γ and PPAR-γ-regulated genes after TQ treatment. MCF-7 cells 
were transfected with PPAR-γDN or pCMX plasmids for 12-14 h before treatment 
with 40 µM TQ for 24 h. Whole cell lysate was then collected for Western blot 
analysis. The data are representative of at least three independent experiments. * 




3.4  Studies to investigate the role of ROS in the anticancer activities of 
 TQ 
3.4.1  Effect of TQ on ROS production 
The induction effect of TQ on ROS production as a mechanism to cause 
cancer cell death has been reported in primary effusion lymphoma cells, DLD-
1 human colon cancer cells, C4-2B prostate cancer cells and Jurkat cells (Woo 
et al., 2012). Whether ROS induction was also involved in TQ-induced 
apoptosis in breast cancer cells was investigated. By using flow cytometry 
after Mitosox staining, our data showed that TQ significantly induced ROS 
level in a time-dependent manner (Figure 3.4.1A). ROS level was maximal at 
3 h TQ exposure and slightly decreased at 6 h. Pre-treatment with N-
acetylcysteine (NAC), a strong anti-oxidant, could abrogate TQ-induced ROS 
production in both MCF-7 (Figure 3.4.1B) and MDA-MB-231 cell lines 
(Figure 3.4.1C).  
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Figure 3.4.1 Effect of TQ on ROS production in breast cancer cells.  
(A) Time-response effect of TQ on ROS level. MCF-7 cells were treated with 40 µM 
TQ for various incubation periods ranging up to 6 h. The cells were analyzed by flow 
cytometry after Mitosox staining. Values are means ± S.E.M. of at least three 
independent experiments. * p<0.05 vs. negative control. (B) Effect of NAC on TQ-
induced ROS production in MCF-7 cells. Cells were pre-treated with 1 or 5 mM NAC 
for 2 h before exposure to 40 µM TQ for 3 h. The cells were analyzed by flow 
cytometry after Mitosox staining. Values are means ± S.E.M. of at least three 
independent experiments. * p<0.05, ** p<0.01, *** p<0.001. (C) Effect of NAC on 
TQ-induced ROS production in MDA-MB-231 cells. Cells were pre-treated with 5 
mM NAC for 2 h before exposure to 40 µM TQ for 3 h. The cells were analyzed by 
flow cytometry after Mitosox staining. Values are means ± S.E.M. of at least three 
independent experiments. ** p<0.01, *** p<0.001.  
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3.4.2  The role of ROS in the cytotoxic effect of TQ 
In order to study the role of TQ-induced ROS in the cytotoxicity of TQ, NAC 
was used to block the induction of ROS. By using MTT assay, our data 
showed that TQ’s growth inhibition effect could be abrogated by NAC in a 
dose-dependent manner. Pre-treatment with 5 mM NAC could reverse TQ-
induced growth inhibition almost completely in both MCF-7 (Figure 3.4.2A) 
and MDA-MB-231 cells (Figure 3.4.2B). These results demonstrate that TQ’s 












Figure 3.4.2 Effect of NAC on TQ-induced cytotoxicity in breast cancer cells.  
(A) MCF-7 and (B) MDA-MB-231 cells were pre-treated with 1 or 5 mM NAC for 2 
h before exposure to increasing concentrations of TQ for 24 h. The cells were then 
analyzed with MTT assay. Values are means ± S.E.M. of at least three independent 
experiments. * p<0.05, ** p<0.01, *** p<0.001 vs. PBS control.  
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3.4.3  The role of ROS in TQ-induced apoptosis 
Whether TQ-induced ROS played a role in the pro-apoptotic effect of TQ was 
also investigated. Our results showed that the increased percentage of annexin 
V positive cells induced by TQ could be completely reversed by NAC pre-
treatment (Figure 3.4.3A). Moreover, the cleavage of PARP protein induced 
by TQ in MCF-7 (Figure 3.4.3B) and MDA-MB-231 cells (Figure 3.4.3C) 
could also be reversed by NAC pre-treatment. These results suggest that ROS 
indeed play a crucial role in TQ-induced apoptosis.   
 
             
 




                                
                   
 
                              
 
Figure 3.4.3 The role of ROS in TQ-induced apoptosis.  
(A) Effect of NAC on TQ-induced increased percentage of annexin V positive cells. 
MCF-7 cells were pre-treated with 5 mM NAC for 2 h before exposure to 40 µM TQ 
for 12 h. The cells were then analyzed with annexin V assay. Values are means ± 
S.E.M. of at least three independent experiments. * p<0.05, ** p<0.01. (B) Effect of 
NAC on TQ-induced PARP-cleavage in MCF-7 cells. Cells were pre-treated with 5 
mM NAC for 2 h before exposure to 40 µM TQ for 12 h. Whole cell lysate was 
collected for Western blot analysis. Data are a representative of at least three 
independent experiments. * p<0.05. (C) Effect of NAC on TQ-induced PARP-
cleavage in MDA-MB-231 cells. Cells were pre-treated with 5 mM NAC for 2 h 
before exposure to 40 µM TQ for 12 h. Whole cell lysate was collected for Western 
blot analysis. Data are a representative of at least three independent experiments.  
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3.4.4  The role of ROS in mediating the effect of TQ on various anti-
 apoptotic genes  
Previous experiments have shown that TQ treatment was able to suppress the 
protein expression of various anti-apoptotic genes including survivin, XIAP, 
Bcl-xL and Bcl-2. Whether ROS involved in these suppressions was also 
examined. NAC was used to block the induction of ROS. As shown in Figure 
3.4.4, our data showed that NAC pre-treatment could reverse the suppression 
of survivin, XIAP, Bcl-xL and Bcl-2 protein expression induced by TQ. These 
results demonstrate that TQ-induced apoptosis was mediated via induction of 
ROS, which in turn, suppressing the expression of these anti-apoptotic gene 













         
     
 
Figure 3.4.4 Effect of TQ-induced ROS on the protein expression of various anti-
apoptotic genes.  
MCF-7 cells were pre-treated with 5 mM NAC for 2 h before exposure to 40 µM TQ 
for 12 h. Whole cell lysate was collected for Western blot analysis. Data are a 
representative of at least three independent experiments. * p<0.05, ** p<0.01 vs. 
negative control.  
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3.4.5  The relationship between ROS and PPAR-γ in the mechanism of 
action of TQ 
Since ROS and PPAR-γ were found to be both involved in the anticancer 
activities of TQ, whether these two pathways linked to each other was also 
investigated. Our results showed that NAC pre-treatment could reverse the 
increase of PPAR-γ expression induced by TQ in MCF-7 cells, and also 
reverse the decrease of PPAR-γ expression induced by TQ in MDA-MB-231 
cells (Figure 3.4.5A). These results suggested that the changes in PPAR-γ 
expression were due to the increase in ROS production induced by TQ. On the 
other hand, pre-treatment with GW9662 did not cause any significant change 
in TQ-induced ROS level. Together, these results suggest that PPAR-γ could 
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Figure 3.4.5 The relationship between ROS and PPAR-γ in the mechanism of 
action of TQ.  
(A) Effect of NAC on PPAR-γ expression after TQ treatment. MCF-7 and MDA-MB-
231 cells were pre-treated with 5 mM NAC for 2 h before exposure to 40 µM TQ for 
12 h. Whole cell lysate was collected for Western blot analysis. Data are a 
representative of at least three independent experiments. * p<0.05, ** p<0.01 vs. 
negative control. # p<0.05. (B) Effect of GW9662 on TQ-induced ROS level. MCF-7 
cells were pre-treated with 10 µM GW9662 for 2 h before exposure to 40 µM TQ for 
3 h. The cells were then analyzed with flow cytometry after Mitosox staining. Values 
are means ± S.E.M. of at least two or three independent experiments. * p<0.05.  
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3.5  Studies on the role of p38 MAPK in the anticancer activities of TQ 
3.5.1  Effect of TQ on various MAPKs 
The effect of TQ on MAPKs pathway was investigated by examined the 
protein expression of p-ERK/ERK, p-JNK/JNK and p-p38/p38 after TQ 
treatment. Our data showed that TQ treatment increased the phosphorylation 
of ERK, JNK and p38 in MCF-7 cells with no change in their respective total 
protein. The increase of JNK phosphorylation started as early as 4 h TQ 
exposure and this increase was maintained till 12 h TQ exposure. The increase 
of p38 phosphorylation occurred in a time-dependent manner, and was 
maximal at 12 h TQ exposure. The increase of ERK phosphorylation peaked 














Figure 3.5.1 Effect of TQ on the phosphorylation status of various MAPKs.  
MCF-7 cells were treated with 40 µM TQ for different incubation periods ranging up 
to 12 h. Whole cell lysate was collected for Western blot analysis. The data are 
representative of at least three independent experiments. * p<0.05 vs. negative control.  
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3.5.2  Effect of TQ on p38 activation 
Since p38 is a potential tumor suppressor gene and is a possible downstream 
effector of ROS, its role in the anticancer activities of TQ was next 
investigated. A p38-specific pharmacological inhibitor, SB203580, was used 
to investigate whether it could reverse TQ-induced p38 activation. Our results 
showed that the increased phosphorylation of p38 induced by TQ in MCF-7 
and MDA-MB-231 cells could be abrogated by SB203580 pre-treatment 
(Figure 3.5.2A). Similar finding was also obtained with p38 ELISA kit 
whereby SB203580 could abrogate TQ-induced increased level of p-p38 
















Figure 3.5.2 Effect of SB203580 on TQ-induced p38 activation.  
(A) Effect of SB203580 on TQ-induced p38 phosphorylation. MCF-7 and MDA-MB-
231 cells were pre-treated with 10 µM SB203580 for 1 h before exposure to 40 µM 
TQ for 12 h. Whole cell lysate was collected for Western blot analysis. Data are a 
representative of at least three independent experiments. * p<0.05, ** p<0.01. (B) 
The effect of SB203580 on TQ-induced p-p38 level. MCF-7 and MDA-MB-231 cells 
were pre-treated with 10 µM SB203580 for 1 h before exposure to 40 µM TQ for 12 
h. Whole cell lysate was analyzed with PathScan® phospho-p38 MAPK 
(Thr180/Tyr182) sandwich ELISA kit as described under Materials and Methods 
section. Values are means ± S.E.M. of at least three independent experiments. * 
p<0.05, *** p<0.001.  
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3.5.3  The role of p38 activation on the cytotoxicity of TQ 
We next investigated the role of p38 activation in the cytotoxic effect of TQ. 
SB203580 was used to block TQ-induced p38 activation. Our data showed 
that TQ-induced growth inhibition could be abrogated by SB203580 pre-
treatment, at least partially, in both MCF-7 and MDA-MB-231 cell lines 
(Figure 3.5.3). These results suggest that p38 activation is partially involved in 
the cytotoxic effect of TQ. 
 
                
Figure 3.5.3 Effect of SB203580 on TQ’s growth inhibition effect.  
MCF-7 and MDA-MB-231 cells were pre-treated with 10 µM SB203580 for 1 h 
before exposure to increasing doses of TQ for 24 h. The cells were then analyzed by 
MTT assay. Values are means ± S.E.M. of at least three independent experiments. * 
p<0.05, ** p<0.01.  
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3.5.4  The role of p38 activation on TQ-induced apoptosis 
We also investigated whether p38 activation is involved in TQ-induced 
apoptosis. As shown in Figure 3.5.4A, TQ-induced increased percentage of 
annexin V-positive cells could be reversed by SB203580 pre-treatment in both 
MCF-7 and MDA-MB-231 cells. Moreover, the PARP cleavage induced by 
TQ in both MCF-7 and MDA-MB-231 cells could also be reversed by 
SB203580 pre-treatment (Figure 3.5.4B). These results demonstrate that p38 


















           
 
 
Figure 3.5.4 The role of p38 activation on TQ-induced apoptosis.  
(A) Effect of SB203580 on TQ-induced increased percentage of annexin V-positive 
cells. MCF-7 and MDA-MB-231 cells were pre-treated with 10 µM SB203580 for 1 
h before exposure to 40 µM (for MDA-MB-231) or 50 µM (for MCF-7) TQ for 12 h. 
The cells were then analyzed with annexin V assay. Values are means ± S.E.M. of at 
least three independent experiments. * p<0.05, ** p<0.01. (B) Effect of SB203580 on 
TQ-induced PARP-cleavage. MCF-7 or MDA-MB-231 cells were pre-treated with 10 
µM SB203580 for 1 h before exposure to 40 µM TQ for 12 h. Whole cell lysate was 
collected for Western blot analysis. Data are a representative of at least three 
independent experiments.  
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3.5.5  Effect of TQ-induced p38 activation on various anti-apoptotic 
genes  
The effect of TQ-induced p38 activation on various anti-apoptotic genes, such 
as survivin, XIAP, Bcl-xL and Bcl-2, was also examined. We found that these 
proteins could be suppressed by TQ treatment, whereas pre-treatment with 
SB203580 could reverse some of these reductions (Figure 3.5.5). The decrease 
of XIAP induced by TQ in MCF-7 cells was found to be reversed by 
SB203580. On the other hand, the decrease of survivin and Bcl-2 induced by 
TQ in MDA-MB-231 cells could be reversed by SB203580. This difference 
could be due to cell line differences such as ER status and p53 status which 
might interfere with the mechanism of action of TQ on the p38 pathway.  
 






Figure 3.5.5 Effect of TQ-induced p38 activation on the protein expression of 
various anti-apoptotic genes.  
MCF-7 and MDA-MB-231 cells were pre-treated with 10 µM SB203580 for 1 h 
before exposure to 40 µM TQ for 12 h. Whole cell lysate was collected for Western 
blot analysis. Data are a representative of at least three independent experiments. * 




3.5.6  Effect of p38 siRNA gene silencing on TQ-induced apoptosis 
In addition to p38-specific inhibitor, we also used p38 siRNA gene silencing 
to study the role of p38 activation on the pro-apoptotic effect of TQ. The 
effect of p38 siRNA gene silencing was first validated using Western blot. As 
shown in Figure 3.5.6A, p38 siRNA gene silencing could successfully 
suppress both the expression of p-p38 and p38. Next, our data showed that p38 
siRNA gene silencing could abrogate TQ-induced increased percentage of 
annexin V positive cells (Figure 3.5.6B). Moreover, p38 siRNA gene silencing 
could also reverse TQ-induced PARP cleavage (Figure 3.5.6C). These results 
confirmed the role of p38 activation in TQ-induced apoptosis.  
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Figure 3.5.6 Effect of p38 siRNA gene silencing on TQ-induced apoptosis.  
MCF-7 cells were transfected with 30 nM p38 siRNA or siRNA-A for 6 h followed 
by at least 24 h recovery with serum-added medium. The cells were then treated with 
40 µM TQ for 12 h. (A) Effect of p38 siRNA gene silencing on the protein expression 
of p-p38 and p38. Whole cell lysate was collected for Western blot analysis. Data are 
a representative of at least three independent experiments. * p<0.05, *** p<0.001 vs. 
negative control. (B) Effect of p38 siRNA gene silencing on TQ-induced increased 
percentage of annexin V positive cells. The cells were analyzed with annexin V assay. 
Values are means ± S.E.M. of at least three independent experiments. * p<0.05. (C) 
Effect of p38 siRNA gene silencing on TQ-induced PARP cleavage. Whole cell 
lysate was collected for Western blot analysis. Data are a representative of at least 
three independent experiments. * p<0.05 vs. negative control. 
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3.5.7  The relationship between ROS and p38 in the mechanism of action 
 of TQ  
There are studies suggested that the interaction of ROS and p38 was 
responsible for certain anticancer activities as shown in several types of 
carcinoma (Bragado et al 2007; Kang and Lee 2008). Thus, whether the 
mechanism of action of TQ involved the interaction between ROS and p38 
was investigated here. By changing the level of ROS using NAC, TQ-induced 
increased phosphorylation of p38 was prevented (Figure 3.4.6A). The data 
from p38 ELISA kit also showed that TQ was able to significantly increase the 
p-p38 level which could be abrogated by NAC pre-treatment (Figure 3.4.6B). 
These results demonstrate that TQ-induced ROS indeed play an important role 
in p38 activation. Next, whether p38 activation interfered the level of ROS 
was also examined. As shown in Figure 3.4.6C, SB203580 pre-treatment did 
not cause significant change on TQ-induced ROS level. Together, these results 
showed that p38 activation is mediated through TQ-induced ROS.  
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Figure 3.5.7 The relationship between ROS and p38 in the mechanism of action 
of TQ.  
(A) Effect of NAC on TQ-induced p38 phosphorylation. MCF-7 cells were pre-
treated with 5 mM NAC for 2 h before exposure to 40 µM TQ for 12 h. Whole cell 
lysate was collected for Western blot analysis. Data are a representative of at least 
three independent experiments. * p<0.05, ** p<0.01 (B) Effect of NAC on TQ-
induced p-p38 level. MCF-7 cells were pre-treated with 5 mM NAC for 2 h before 
exposure to 40 µM TQ for 12 h. Whole cell lysate was analyzed with PathScan® 
phospho-p38 MAPK (Thr180/Tyr182) sandwich ELISA kit. Values are means ± 
S.E.M. of at least three independent experiments. ** p<0.01. (C) Effect of SB203580 
on TQ-induced ROS production. MCF-7 cells were pre-treated with 10 µM 
SB203580 for 1 h before exposure to 40 µM TQ for 1 or 3 h. The cells were then 
analyzed with flow cytometry after Mitosox staining. Values are means ± S.E.M. of 




3.5.8  The relationship between p38 and PPAR-γ in the mechanism of 
 action of TQ  
Since p38 and PPAR-γ are both involved in the anticancer activities of TQ, 
whether these two pathways linked to each other was also investigated. Our 
data showed that SB203580 pre-treatment did not cause significant change in 
the protein expression of PPAR-γ in MDA-MB-231 cells, but slightly 
increased the PPAR-γ expression in MCF-7 cells (Figure 3.5.7A). 
Interestingly, GW9662 pre-treatment appeared to increase p38 
phosphorylation in MCF-7 cells, while no change was observed in MDA-MB-
231 cells (Figure 3.5.7B). These results showed that p38 and PPAR-γ might 














     
 
Figure 3.5.8 The relationship between p38 and PPAR-γ in the mechanism of 
action of TQ.  
(A) Effect of SB203580 on the protein expression of PPAR-γ after TQ treatment. 
MCF-7 and MDA-MB-231 cells were pre-treated with 10 µM SB203580 for 1 h 
before exposure to 40 µM TQ for 12 h. Whole cell lysate was collected for Western 
blot analysis. Data are a representative of at least three independent experiments. * 
p<0.05, ** p<0.01, *** p<0.001 vs. negative control. (B) Effect of GW9662 on the 
protein expression of p-p38/p38 after TQ treatment. MCF-7 and MDA-MB-231 cells 
were pre-treated with 10 µM GW9662 for 2 h before exposure to 40 µM TQ for 12 h. 
Whole cell lysate was collected for Western blot analysis. Data are a representative of 





3.6  Studies on the antitumor effect of TQ in the breast tumor 
xenograft mouse model 
3.6.1  Effect of TQ on the growth of breast tumor xenograft 
In addition of in vitro experiments, in vivo study was also performed to 
provide clinical relevance for the anticancer activities of TQ. A high number 
(107 cells/mouse) of MDA-MB-231 cells was injected subcutaneously to 
develop tumor xenograft in the right flank region of female nude mice. The 
treatment was started when the tumor volume was about 100 mm3. Our data 
showed that TQ alone (4 mg/kg TQ, and 8 mg/kg TQ) was able to 
significantly suppress the tumor growth compared to the vehicle group (Figure 
3.6.1A). The effect of TQ alone was also comparable to the positive control 
(2.5 mg/kg Dox). However, these treatments could not completely eradicate 
the tumor or maintain the tumor size at the starting level (Figure 3.6.1A). On 
the other hand, the combined treatment (4 mg/kg TQ + 2.5 mg/kg Dox) not 
only suppressed tumor growth more significantly than the vehicle group, but 
also more significantly than either agent alone (Figure 3.6.1A). Although the 
combined treatment could not completely eradicate the tumor, this treatment 
maintained the tumor size at the starting level throughout the treatment period 
(Figure 3.6.1A). Together, these results showed that TQ alone was able to 
inhibit tumor growth and the combination with chemotherapeutic agent 
produced greater antitumor effect. Photographs of extracted tumors from each 









          
      
Figure 3.6.1 Changes in tumor volume in different treatment groups.  
(A) When tumor volume reached 100 mm3, the mice were divided into five treatment 
groups, each n=5. Group I: saline water/vehicle (i.p., 6 days per week), group II: 4 
mg/kg TQ (i.p., 6 days per week), group III: 8 mg/kg TQ (i.p., 6 days per week), 
group IV: 2.5 mg/kg Dox (i.p., once per week), and group V: 2.5 mg/kg Dox (i.p., 
once per week) + 4 mg/kg TQ (i.p., 6 days per week). Tumor volume was measured 
with Vernier calipers and calculated with the formula, Volume = (width2 X length)/2. 
Values are means ± S.D. of each group. * p<0.05, *** p<0.001 vs. vehicle control 
group. # p<0.05. (B) Photographs of extracted tumors from each treatment group.   
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3.6.2  Effect of TQ on mouse body weight 
Whether TQ treatment caused any possible adverse effect to the mice was also 
examined. No visible adverse effect was observed during or after drug 
injection. The slight decrease in mouse weight (< 9% compared to the starting 
value) in TQ-treated groups suggested that TQ caused little or no toxicity to 
mouse health (Figure 3.6.2). However, further toxicity study is needed to 
address this issue in greater detail.  
 
 
Figure 3.6.2 Mouse body weight relative to the starting measurement.  





3.6.3  Effect of TQ on tumor structure (H&E staining) 
In order to study the structure of tumors from all treatment groups, the tumor 
tissues were stained with H&E followed by microscopy observation. As 
shown in Figure 3.6.3, the tumor observation of vehicle group displayed high 
grade tumor with irregular cell arrangement and intact tissue structure. In 
contrast, the tumors from TQ-treated groups were considerably tightly packed 
cells, decrease in stroma and increase in necrotic cells suggesting tumor 














3.6.4  Effect of TQ on the level of apoptosis in tumor tissues (TUNEL 
 staining) 
TUNEL staining was used to examine the level of apoptosis in tumor tissues 
from each treatment group, while DAPI was used to stain nucleus. From the 
results, TQ-treated groups showed a greater number of fluorescence than the 
vehicle group (Figure 3.6.4A). By counting the average number of TUNEL 
positive cells in drug treatment groups as compared to the vehicle group, we 
found that the single-drug treatment groups (4 mg/kg TQ, 8 mg/kg TQ, and 
2.5 mg/kg Dox) had about 2-fold higher number of TUNEL positive cells than 
the vehicle group, while the combined group showed the highest number of 
TUNEL positive cells (Figure 3.6.4B). These results showed that the tumor 
suppression effect of TQ was due to apoptosis.   
       A 











                   
Figure 3.6.4 TUNEL staining of tumor tissues from different treatment groups.  
(A) Fluorescence microscopy observation of TUNEL and DAPI staining. (B) The 
average number of TUNEL-positive cells per field. Values are means ± S.D. of three 
photographs. * p<0.05, ** p<0.01 vs. vehicle control group.  
102 
 
3.6.5 Effect of TQ on the proliferation rate of tumor tissues (Ki67              
 immunohistochemical staining) 
Ki67 is a protein marker for cellular proliferation, thus we were interested to 
study its expression in the tumor tissues after TQ treatment. Our data showed 
that the tumor tissues of drug treatment groups expressed significantly 
decreased Ki67 protein compared to the vehicle group (Figure 3.6.5A). By 
calculating the number of Ki67 positive cells as compared to the vehicle group, 
we found that the single-drug treatment groups contained at least 60% lesser 
Ki67 positive cells than the vehicle group, while the combined group showed 
the lowest number of Ki67 positive cells (Figure 3.6.5B).  
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Figure 3.6.5 Ki67 immunohistochemical staining of tumor tissues from different 
treatment groups.  
(A) Fluorescence microscopy observation of Ki67 and DAPI staining. (B) The 
average number of Ki67-positive cells per field. Values are means ± S.D. of three 





3.6.6  Effect of TQ on the expression of various genes in tumor tissues 
The protein expression of various genes, such as p-p38/p38, PPAR-γ and anti-
apoptotic genes, in TQ-treated tumor tissues was examined and these results 
were compared to those from in vitro studies. Figure 3.6.6 showed that TQ 
was able to increase p38 phosphorylation in the tumor tissues, which was in 
line with the cell line data. On the other hand, PPAR-γ was decreased in TQ-
treated groups. Since these tumors were induced from MDA-MB-231 cells, 
and our previous study had shown that TQ could reduce PPAR-γ expression in 
MDA-MB-231 cells (in contrast to MCF-7), it was deduced that TQ treatment 
was able to suppress PPAR-γ expression both in vitro and in vivo of MDA-
MB-231 cell origin. In addition, our results showed that TQ was able to 
suppress the protein expression of various anti-apoptotic genes including 
XIAP, Bcl-xL, Bcl-2 and survivin in the tumor tissues (Figure 3.6.6). These 
results showed that the apoptosis induced by TQ in the tumor tissues could be 
due to the suppression of these anti-apoptotic genes.  
 





Figure 3.6.6 Effect of TQ on the protein expression of various genes in tumor 
tissues.  
Tissue lysate was collected for Western blot analysis. Data are representative of at 






3.6.7  Effect of TQ on the level of anti-oxidant enzymes/molecules in 
mouse liver tissues 
The hepatic level of anti-oxidant enzymes/molecules was measured to 
investigate how ROS-inducing TQ interfered with the oxidation status in the 
liver. Our data showed that the catalase level was significantly increased in the 
drug treatment groups compared to the vehicle group (Figure 3.6.7A). The 
combined group had the highest catalase level among all treatment groups, and 
also significantly higher than either agent alone (Figure 3.6.7A). In addition, 8 
mg/kg TQ and 2.5 mg/kg Dox treatment groups were able to increase the SOD 
level in the liver tissues compared to the vehicle group. 4 mg/kg TQ and the 
combined groups showed higher SOD level than the vehicle group, but these 
differences were not significant (Figure 3.6.7B). Moreover, TQ-alone 
treatment groups (4 mg/kg TQ, and 8 mg/kg TQ) showed significantly higher 
level of hepatic glutathione than the vehicle group (Figure 3.6.7C), while 2.5 
mg/kg Dox group showed decreased level of glutathione. Interestingly, the 
combined group had lower glutathione level than the vehicle group, but higher 
than 2.5 mg/kg Dox group (Figure 3.6.7C).  
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Figure 3.6.7 The level of hepatic anti-oxidant enzymes/molecules in each 
treatment group.  
(A) Effect of TQ on the level of catalase in mouse liver tissues. Liver tissues were 
harvested for catalase assay. Values are means ± S.E.M. of at least three independent 
experiments. * p<0.05, ** p<0.01, *** p<0.001 vs. vehicle control group. # p<0.05, 
## p<0.01. (B) Effect of TQ on the level of SOD in mouse liver tissues. Liver tissues 
were harvested for SOD assay. Values are means ± S.E.M. of at least three 
independent experiments. * p<0.05 vs. vehicle control group. (C) Effect of TQ on the 
level of glutathione in mouse liver tissues. Liver tissues were harvested for 
glutathione assay. Values are means ± S.E.M. of at least three independent 
experiments. ** p<0.01, *** p<0.001 vs. vehicle control group. ### p<0.001. 
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4  DISCUSSION 
4.1 General discussion 
Due to increasing incidence and death rate from cancer in the United States, 
US President Richard Nixon declared the “War on Cancer” in 1971 in an 
effort to find cures for cancer disease through extensive research. Despite 
massive development in the last several decades, little has changed with regard 
to the incidence and mortality rate of this disease. Why has the discovery of 
anticancer drug been so difficult? The reason could lie with the disease itself. 
Cancer is a multi-complex disease arising from multiple signaling pathways 
that affect cell survival and development. Following the identification of the 
targets for an anticancer drug, the most important consideration is to make 
distinction on whether the targets have essential or non-essential functions 
(Kamb et al., 2007). Inhibition of essential functions can be fatal to the cancer 
cells, but also resulting in narrow therapeutic window owing to the 
requirement of these functions in normal cells. Inhibitors of non-essential 
functions have limited efficacy but are usually well tolerated in the human 
body. The issue on single-targeted or multi-targeted drugs is also widely 
discussed in drug discovery. Although single-targeted drugs are specific, 
however, when the dose is increased, off-target toxicity can arise due to the 
inhibition of unintended or unknown functions (Kamb et al., 2007). Kamb et 
al. also suggested that clinicians prefer multi-targeted drugs for maximal 
antitumor effect because they can manage toxicities through other 
interventions (Kamb et al., 2007). With cancer cells carrying mutation of 
about 300 genes and deregulation of 500 gene products, how single-targeted 
drugs treat a multi-complex disease like cancer is still a question (Aggarwal et 
al., 2007).  
Natural products or traditional medicine have a long history in treating various 
kinds of illness including cancer. Because these medicines have been used in 
human body for many generations, any possible adverse effects/toxicities have 
been well identified and likely manageable. Generally, these medicines target 
multiple signaling pathways. As such, many researchers take an advantage on 
this property to discover potential anticancer drug. For example, curcumin, 
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luteolin and ursolic acid are natural products that have received extensive 
attention for their potential inhibitory effects in various types of carcinoma. 
Thus, in this project, we focused on the anticancer activities of thymoquinone, 
a natural product isolated from Nigella sativa, in breast carcinoma and tried to 
elucidate its mechanism of action in multiple signaling pathways.  
 
 
4.2  Cytotoxic and pro-apoptotic effects of TQ 
TQ has been shown to exhibit cytotoxic effect in many different kinds of 
cancer cells such as leukemia (HL-60 and Jurkat) (El-Mahdy et al., 2005; 
Alhosin et al., 2010), lung (NCI-H460 and A549) (Jafri et al., 2010; Rooney et 
al., 2010), colorectal (HT-29, HCT-116, DLD-1, Lovo and Caco-2) (El-Najjar 
et al., 2010; Rooney et al., 2010), pancreatic (MIA PaCa-2, HPAC and BxPC-
3) (Banerjee et al., 2009; Rooney et al., 2010) and prostate cancer (LNCaP, 
C4-2B, DU145 and PC-3) (Kaseb et al., 2007; Koka et al., 2010). However, 
the cytotoxicity of TQ in breast cancer cells was not explained until we began 
this project. Our results showed that TQ treatment was able to suppress the 
growth of MCF-7, MDA-MB-231 and BT-474 breast cancer cells in a dose- 
and time-dependent manner. MCF-10A normal breast cells were also 
vulnerable to the toxicity of TQ, however this cell line was less sensitive to 
TQ than MDA-MB-231 and BT-474 cell lines. Thus, by determining the 
optimal dose, TQ can be used to target certain breast cancer cells with little or 
no toxicity to normal cells. Indeed, TQ was reported to cause little or no 
toxicity in several non-cancerous cell lines such as BPH-1 prostate epithelial 
cells (Kaseb et al., 2007), IMR90 human normal lung fibroblast cells (Gurung 
et al., 2010) and FHs74Int human normal intestinal cells (El-Najjar et al., 
2010). Moreover, it has been shown that human body could tolerate a dose of 
TQ up to 2600 mg/day (Al-Amri et al., 2009). However, whether TQ is safe 
for long term use in human body is still remain to be studied.   
MTT assay was used in this project to access the viability of treated cells. The 
principle of this assay is based on the ability of NAD(P)H-dependent cellular 
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oxidoreductase enzymes in live cells which capable of reducing the 
tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide to its insoluble formazan crystals, which produce purple color after 
dissolving with DMSO. The properties of this assay are rapid, quantitative, 
and highly reproducible with a low intra-test variation between data points. 
However, under certain conditions, MTT assay may not accurately access cell 
viability (Wang et al., 2010). For example, rapidly replicating cells have 
higher rate of MTT reduction due to high metabolic rate. Moreover, some 
resting cells such as thymocytes and splenocytes, are viable but not necessarily 
display high metabolic activity. Alternative markers of cell dead should be 
used, for example cell membrane damage/leakage. As such, we also 
investigated the cytotoxicity of TQ via other assays such as propidium iodide 
staining and Annexin V assay.    
In the present, there are a few studies reporting the anticancer effect of TQ on 
breast cancer cells. It was shown that TQ inhibited Akt, which in turn, 
suppressed cyclin D1 leading to G1 arrest in MDA-MB-468 and T-47D cells 
(Rajput et al., 2013). TQ was found to up-regulate PTEN for apoptotic cell 
death in doxorubicin-resistant MCF-7 cells (Arafa et al., 2011). Interestingly, 
there is a study reported that TQ was not able to kill MCF-7 cells due to high 
expression of NADPH quinone oxidoreductase 1, whereby inhibition of 
NADPH quinone oxidoreductase 1 with dicoumarol could render MCF-7 cells 
to TQ-sensitive (Sutton et al., 2012). 
We showed that TQ did not cause cell cycle arrest in MCF-7 cells. This result 
was further explained by no significant change in the protein expression of cell 
cycle genes, including cyclin D1 and cyclin E, in TQ-treated MCF-7 cells. 
Interestingly, there was an increase in G2/M phase at 24 h time point even in 
the negative control group. Since these cells were synchronized with serum-
free media before used in the experiment, the increase of G2/M phase might 
be due to cell cycle progression when the cells were released from starvation. 
On the other hand, there are studies reported that TQ was able to induce 
G0/G1 arrest or G2/M arrest in different types of cancer cells. For example, 
TQ was shown to induce G0/G1 arrest in SP-1 mouse papilloma carcinoma 
cells possibly through the increase of p16 and decrease of cyclin D1 (Gali-
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Muhtasib et al., 2004b). In addition, TQ was found to induce G0/G1 arrest in 
acute lymphoblastic leukemia Jurkat cells through p73-mediated pathway, as 
confirmed by p73 siRNA gene silencing which could reactivate the cell cycle 
progression (Alhosin et al., 2010). On the other hand, TQ induced G2/M arrest 
in I7 mouse spindle carcinoma cells with increased p53 and decreased cyclin 
B (Gali-Muhtasib et al., 2004b). Moreover, G2/M arrest was also observed in 
MNNG/HOS human osteosarcoma cells after TQ treatment together with the 
increased expression of p21WAF1 (Roepke et al., 2007). Together, these results 
demonstrate that the cell cycle arrest induced by TQ, whether it is G0/G1 or 
G2/M arrest, is highly dependent on the cell lines used.  
In this study, TQ was found to induce apoptosis in MCF-7 cells as shown by 
increased percentage of Annexin V positive cells and increased PARP-
cleavage. In addition of increased Bax/Bcl-2 ratio, TQ could decrease the 
expression of pro-caspases 8, 9 and 7. Thus, we suggest that TQ-induced 
apoptosis in MCF-7 cells might involve both intrinsic and extrinsic apoptosis 
pathways. TQ has been shown to induce apoptosis in different kinds of cancer 
cells such as liver, lung, colon and prostate cancer (Woo et al., 2012). There 
are studies reported that TQ-induced apoptosis was mediated possibly through 
p53, p73, STAT3, PTEN and NF-κB pathways (Woo et al., 2012). For 
example, TQ-induced apoptosis in HCT116 human colorectal carcinoma cells 
could be blocked by p53-specific inhibitor, pifithrin-α (Gali-Muhtasib et al., 
2004a). This was further explained by another study showing that p53-null 
HCT116 cells were resistance to TQ-induced apoptosis (Gali-Muhtasib et al., 
2008a). In contrast, apoptosis was observed in TQ-treated p53-null 
myeloblastic leukemia HL-60 cells, suggesting a p53-independent pathway 
(El-Mahdy et al., 2005). p73, a protein homologue to p53, is also involved in 
TQ-induced apoptosis. For example, TQ was shown to induce apoptosis in 
p53-null acute lymphoblastic leukemia Jurkat cells through the activation of 
p73 pathway, whereby p73 siRNA gene silencing could prevent TQ-induced 
cell death (Alhosin et al., 2010). In addition, TQ was reported to inhibit both 
constitutive and IL-6-inducible STAT3 phosphorylation in U266 multiple 
myeloma cells (Li et al., 2010). Interestingly, STAT3 over-expression or 
deletion could rescue U266 cells from TQ-induced apoptosis (Li et al., 2010). 
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Moreover, TQ was shown to activate PTEN for apoptotic cell death, whereby 
PTEN knockdown by siRNA gene silencing could abrogate TQ-induced 
apoptosis (Arafa et al., 2011). TQ was found to suppress TNF-induced NF-κB 
activation and NF-κB-regulated anti-apoptotic gene products such as IAP1, 
IAP2, XIAP, Bcl-2, Bcl-xL, and survivin (Sethi et al., 2008). Moreover, TQ 
was found to inhibit NF-κB in SaOS-2 human osteosarcoma cells and SaOS-2-
induced tumors (Peng et al., 2013). Taken together, these results suggest that 
TQ is a multi-targeted, pro-apoptotic anticancer drug.    
Moreover, our data showed that the combination of TQ with chemotherapeutic 
agents, such as doxorubicin and 5-fluorouracil, could result in enhanced 
cytotoxicity in MCF-7 cells. This enhanced inhibitory effect was significantly 
higher than either agent alone. This kind of synergistic effect has been 
reported in NCI-H460 non-small cell lung cancer cells by combining TQ with 
cisplatin (Jafri et al., 2010). Moreover, pre-treating TQ to human pancreatic 
cells (HPAC and BxPC-3) could sensitize these cells to the growth inhibition 
effect of gemcitabine and oxaliplatin (Banerjee et al., 2009). In addition, TQ 
was found to potentiate the apoptosis induced by bortezomib and thalidomide 
in U266 multiple myeloma cells (Li et al., 2010). Moreover, TQ could 
potentiate MCF-7 and T47D human breast adenocarcinoma cells to the 
cytotoxic effect of radiation (Velho-Pereira et al., 2011), which make it a 
potential drug for neoadjuvant chemotherapy. The synergism of the 
combination of TQ and chemotherapeutic drugs on cytotoxicity could be 
explained by down-regulation of NF-κB, Bcl-2 family, and NF-κB–dependent 
anti-apoptotic signaling (Banerjee et al., 2009). This is further supported by 
another study showing that down-regulation of NF-κB by TQ could sensitize 
cancer cells to the action of platinum drugs (Nessa et al., 2011). Together, 
these reports demonstrate that TQ is effective in suppressing cancer cells, 
while it also can combine with chemotherapeutic agents for greater therapeutic 
effect. Our data expanded the list by explaining the cytotoxic effect of TQ 
alone or in combination with chemotherapeutic agents on breast cancer cells.  
In addition, there are a number of studies reported the analogs of TQ which 
could produce greater efficacy. The chemical structure of TQ was modified to 
achieve greater efficacy and higher cellular uptake (Woo et al., 2012). 6-
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hencosahexaenyl conjugate of TQ (fatty acid conjugate) was reported to 
exhibit greater cytotoxic and pro-apoptotic effects than its parent compound in 
518A2 melanoma and HL-60 leukemia cells possibly through increased ROS 
generation (Breyer et al., 2009). TQ-loaded poly-(D, L lactide-co-glycolide) 
nanoparticles were found to be more potent on anti-oxidant activity and 
growth inhibitory effect in MDA-MB-231 breast cancer cells (Ganea et al., 
2010). Moreover, TQ poly-(lactide-co-glycolide) nanoparticles were more 
potent in inhibiting NF-kB, cyclin D1, MMP-9 and VEGF compared to TQ 
(Ravindran et a., 2010). The same study also showed that TQ poly-(lactide-co-
glycolide) nanoparticles were able to produce greater cytotoxicity in MCF-7 
breast cancer, KBM-5 myeloid leukemia, PC-3 prostate cancer, HCT116 colon 
cancer and U266 multiple melanoma cells than its parent compound 
(Ravindran et a., 2010). Modification at the carbonyl or benzenoid sites using 
single pot synthesis was able to produce TQ analog that exhibited greater 
cytotoxic and pro-apoptotic effects in MiaPaCa-2 (gemcitabine-resistant) 
pancreatic cancer cells (Banerjee et al., 2010). The same study also showed 
that this kind of TQ analog could sensitize MiaPaCa-2 cells to the cytotoxicity 
and apoptosis induced by gemcitabine or oxaliplatin (Banerjee et al., 2010). 
TQ analogs appended with gallate and fluorogallate pharmacophores showed 
greater cytotoxicity in pancreatic cancer cells as well as combined with 
gemcitabine for enhanced cytotoxic effect (Yusufi et al., 2013). Together, 
these studies demonstrate the potential of TQ analogs in inhibiting cancer cells. 
However, the efficacy of these analogs is yet to be explained in animal models. 
 
 
4.3  Anti-metastatic effect of TQ 
In addition to cytotoxic and pro-apoptotic effects, TQ was also found to 
exhibit anti-metastatic effect in breast cancer cells. In the present study, our 
data showed that TQ treatment could inhibit MCF-7 and MDA-MB-231 cell 
migration, as well as the invasion of MDA-MB-231 cells in a dose-dependent 
manner. The suppressive effect of TQ in MDA-MB-231 cell invasion was also 
reported by Attoub et al. together with LNM35 lung cancer cells (Attoub et al., 
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2012). Moreover, there are studies reported that TQ was able to suppress C26 
colon (Gali-Muhtasib et al., 2008b) and NCI-H460 lung (Jafri et al., 2010) 
cancer cell invasion. The suppressive effect of TQ was also reported in human 
umbilical vein endothelial cell migration, invasion, and tube formation (Yi et 
al., 2008). The inhibition on human umbilical vein endothelial cell tube 
formation by TQ was in a dose-dependent manner (Peng et al., 2013). TQ was 
found to inhibit CXCL12-mediated chemotaxis in multiple myeloma cell lines 
and primary cells isolated from multiple myeloma patients (Badr et al., 2011). 
Also, Sethi et al. reported that TQ treatment inhibited the protein expression of 
MMP-9, an enzyme involved in the breakdown of extracellular matrix, in 
KBM-5 human myeloid cells (Sethi et al., 2008). Together, these results 
suggest the potential inhibitory effect of TQ in cancer cell metastasis, however, 
the molecular mechanisms involved are not well explained and more results 
from in vivo study are needed to draw a more convincing conclusion.   
“Wound-healing” assay, or also known as scratch assay, is a type of cell 
migration assay. There are other examples of cell migration assay such as 
Boyden chamber assay and cell-exclusion zone assay. “Wound-healing” assay 
is a rapid, convenient and low cost assay that commonly used in research to 
study the movement of cells under various conditions. However, there are 
several drawbacks in this assay, for example it is a 2-D surface and endpoint 
assay, and it is not suitable for non-adherent cells. Moreover, the gap closure 
in this assay is a consequence of a mixture of cell growth and cell migration. 
Perhaps the use of an anti-cell proliferation drug (but not affecting cell 
migration) in this assay could be an approach to explain the gap closure is due 
to cell migration but not cell growth. In this project, the ability of TQ on 
inhibiting gap closure might be a consequence of a mixture of cell death and 
inhibition of cell migration. Therefore, the use of a caspase inhibitor could be 






4.4  The role of the PPAR-γ pathway in the anticancer effects of TQ 
Generally, the risk factors of breast cancer can be divided into two types. The 
first type is the risk factors that cannot be changed, such as age, gender, gene 
mutation (e.g. BRCA1/2), family history, ethnicity and menstrual periods 
(Key et al., 2001; Higa, 2009). The second type of risk factors is amenable to 
change, such as changing in life style and diet, including childbearing, 
breastfeeding, alcohol intake and obesity. Since PPAR-γ is involved in the 
regulation of adipogenesis and lipid metabolism, this receptor has received 
extensive attention for its potential role in tumorigenesis. It was shown that the 
decrease of PPAR-γ expression is associated to the colorectal cancer 
metastatic progression (Pancione et al., 2009).  
A number of studies reported that PPAR-γ activation was able to inhibit tumor 
cell growth. For example, Kumar et al. reported that PPAR-γ activation by 
15d-PGJ2 treatment could inhibit the growth of MCF-7 cells via down-
regulation of NHE1 (Kumar et al., 2009). It has been shown that troglitazone, 
a ligand of PPAR-γ, inhibited MCF-7 cells through G1 arrest by decreasing 
cyclin D1, Cdk2, Cdk4 and Cdk6 (Yin et al., 2001). In this project, we were 
interested on whether the anticancer effects of TQ involved the PPAR-γ 
pathway. Indeed, our results are the first to show that TQ was able to 
specifically activate PPAR-γ, but not other PPARs, in MCF-7 cells. This 
activation was partially involved in the apoptotic effect of TQ, as it could be 
abrogated by pre-treatment with a PPAR-γ-specific inhibitor, GW9662. 
Moreover, the decrease of survivin induced by TQ could be reversed by both 
GW9662 and PPAR-γ dominant negative. These results suggested that the 
suppression of survivin could be due to TQ-induced PPAR-γ activation.  
Molecular docking study of TQ showed that TQ was able to form interactions 
with 7 polar residues and 6 non-polar residues of PPAR-γ molecule, with 
interaction energy of -18.06 kcal/mol (Woo et al., 2011). Among these 
interactions, Ser289, His323, His449, Tyr473 and Phe363 are important for 
PPAR-γ binding and activity (Nolte et al., 1998; Gampe et al., 2000; Salam et 
al., 2008). This suggest that TQ might directly interact with PPAR-γ for 
downstream signaling, in addition of indirect pathway via ROS.  
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In contrast, TQ treatment was shown to down-regulate the PPAR-γ expression 
in MDA-MB-231 cells. We also found that the protein expression of PPAR-γ 
in the breast tumor xenograft induced by MDA-MB-231 cells was also 
decreased in the TQ-treated groups. However, we did not further study 
whether the reduction of PPAR-γ in MDA-MB-231 cells was playing a role in 
the anticancer activities of TQ. There are increasing studies reported the 
reduction of PPAR-γ as a strategy in cancer therapy. Combined treatment of γ-
tocotrienol and PPAR-γ antagonist (GW9662 or T0070907) synergistically 
suppressed the growth of MCF-7 and MDA-MB-231 cells (Malaviya and 
Sylvester, 2013). Moreover, PPAR-γ inhibition via dominant negative PPAR-γ 
mutant (Δ 462) was able to suppress cellular proliferation and induce 
apoptosis in MCF-7 (Zaytseva et al., 2008) and MDA-MB-231 cells (Zaytseva 
et al., 2011). T0070907, a PPAR-γ antagonist, could inhibit breast cancer cell 
proliferation and motility (Zaytseva et al., 2011). In addition, PPAR-γ 
immuno-reactivity was detected in 42% of 238 human breast carcinoma 
tissues (Suzuki et al., 2006). Increase in PPAR-γ activation might not able to 
initiate malignant transformation, however, once an initiating event has taken 
place, aberrant PPAR-γ could contribute to a more aggressive phenotype 
(Zaytseva et al., 2011).  
On the other hand, a recent study reported that PPAR-γ activation was 
required for the apoptotic effect of thiazolidinedione and hydralazine in MDA-
MB-231 cells (Jiang et al., 2011). The treatment of troglitazone could induce 
apoptosis and G1 arrest in MDA-MB-231 cells together with the decrease in 
pRb, cyclin D1, cyclin D2, cyclin D3, Cdk2, Cdk4 and Cdk6 expressions (Yu 
et al., 2008). However, these contradicted with another report which showed 
that delta2-troglitazone, which is devoid of PPAR-γ agonist activity, was able 
to suppress both MCF-7 and MDA-MB-231 cells (Colin et al., 2010). Perhaps 
better pharmacological and molecular approaches are needed to more clearly 
elucidate the role of the PPAR-γ pathway in breast cancer cells, as well as to 
explain the difference in PPAR-γ expression in both MCF-7 and MDA-MB-
231 cell lines after TQ treatment. Currently, there is no study reporting the 




4.5  The involvement of ROS in the anticancer effects of TQ 
Although excessive ROS can damage human tissues during inflammation, 
they can also kill malignant cells. Thus, if this activity can be fully utilized at 
the tumor-specific site, it can serve as a good tool to target tumor cells. In this 
project, we showed that the cytotoxic and pro-apoptotic effects of TQ in MCF-
7 and MDA-MB-231 breast cancer cells were mediated via increase in ROS 
production. In the later experiments, we also showed that the suppression of 
anti-apoptotic gene products, such as XIAP, survivin, Bcl-2 and Bcl-xL, in 
MCF-7 cells was due to TQ-induced ROS production, as shown by the 
reversal of these suppressions by NAC pre-treatment. Although NAC is a 
strong anti-oxidant drug and it could effectively block the effect of TQ, 
additional antioxidant drugs, such as tocotrienol and selenium, can also be 
used to confirm the specificity of TQ on ROS induction.   
Furthermore, TQ-induced ROS production was found to activate p38 for 
apoptotic cell death. Several types of ROS such as singlet oxygen and NO 
have been found to activate the p38 pathway for oxidant-induced apoptosis 
(Matsuzawa and Ichijo, 2005). For example, arsenic trioxide was found to 
induce ROS production, which in turn, activating p38 for apoptosis in HeLa 
human cervical cancer cells (Kang and Lee, 2008). In addition, Butein was 
found to induce ROS production for apoptotic cell death in MDA-MB-231 
cells with decreased ERK and increased p38 (Yang et al., 2012). Chicoric acid, 
a compound found in various edible vegetables, was found to induce apoptosis 
in 3T3-L1 preadipocytes through ROS-mediated p38 activation (Xiao et al., 
2013). On the other hand, there is a report showed that TQ was able to induce 
ROS production for ERK and JNK activations but not p38 in DLD-1 colon 
cancer cells (El-Najjar et al., 2010). This suggested that TQ-induced p38 
activation might be cell line specific. A recent study reported that chlorpyrifos, 
a pesticide, was able to induce cell death and ROS production as well as 
activating MAPKs, including ERK1/2, JNK and p38, in SH-SY5Y human 
neuroblastoma cells; however, it was shown that treatment with MAPK 
inhibitors could inhibit cell death and ROS production (Ki et al., 2013). This 
suggested that p38 could also regulate ROS level under certain conditions.  
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In addition, our data showed that TQ-induced ROS production might play an 
important role in PPAR-γ expression. The increase or decrease of PPAR-γ 
expression in MCF-7 and MDA-MB-231 cells, respectively, after TQ 
treatment could be reversed by NAC pre-treatment. On the other hand, pre-
treatment with GW9662 did not make any significant change to TQ-induced 
ROS production. As such, we suggested that the effect of TQ on ROS was 
upstream of PPAR-γ. Indeed, it was reported that beta-eleostearic acid was 
able to induce apoptotic cell death in T24 human bladder cancer cells possibly 
through ROS-mediated PPAR-γ activation, as shown by the reversal of PPAR-
γ activation by NAC (Sun et al., 2012). This was supported by another study 
showing that NAC could inhibit PPAR-γ expression in 3T3-L1 adipocytes 
(Calzadilla et al., 2011). However, the relationship of ROS and PPAR-γ is not 
always one way. For example, 5,7-dimethoxyflavone, an activator of PPAR-
α/γ, was shown to increase catalase expression, which resulting in the decrease 
of ultraviolet B-induced ROS production (Kim et al., 2012a). Moreover, 
pioglitazone, a PPAR-γ agonist, was found to reduce COX expression and 
ROS production in vascular smooth muscle cells from hypertensive rats 
(Martín et al., 2012). These studies suggested that PPAR-γ could modulate 
anti-oxidant enzymes to regulate the level of ROS. However, in different cases, 
the activation of PPAR-γ can increase ROS level. Troglitazone, a PPAR-γ 
agonist, induced apoptosis and ROS production in HT29 human colon cancer 
cells, which could both be reversed by GW9662 (Wang et al., 2011a). 
Moreover, troglitazone-induced cell death could not be prevented by NAC in 
786-O, Caki-2 and ACHN human renal cell carcinoma cells (Fujita et al., 
2011). Together, these findings suggest the complexity of the relationship 
between ROS and PPAR-γ pathway. While our results suggesting the 
interaction between ROS and PPAR-γ pathway in the anticancer activities of 
TQ, more experiments are needed to describe the importance of this 
relationship in a greater detail. For example, TQ can be exposed to stable 
PPAR-γ overexpressed/knockdown cell line to study the level of ROS and 
apoptosis. 
In addition to MCF-7 cells, TQ has been shown to induce ROS production as a 
mechanism of apoptosis in other carcinoma cells. Recently, a study reported 
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that TQ could induce apoptosis in Jurkat cells via ROS production and 
depletion of glutathione (Dergarabetian et al., 2013). Hussain et al. reported 
that TQ was able to induce ROS production in activated B-cell lymphoma 
cells, which in turn, inhibited NF-κB activation by dephosphorylating IκBα 
and reduced nucleus translocation of p65 subunit (Hussain et al., 2013).  
Moreover, TQ-induced ROS production was found to inhibit Akt activation in 
primary effusion lymphoma cells (Hussain et al., 2011). The role of ROS is 
highly dependent on their levels, with low to modest levels promote tumor 
initiation, while high level suppresses tumor growth (Gupta et al. 2012). Since 
normal cells have higher capacity to cope with ROS before get killed, this 
makes cancer cells to preferentially be targeted by ROS accumulation and die 
selectively (Trachootham et al., 2009). Though ROS are beneficial in 
suppressing tumor cells, a persistent state of oxidative stress can cause cancer 
cells to adapt and become resistant through up-regulation of redox-sensitive 
transcription factors such as NF-κB (Tiligada, 2006; Sullivan and Graham, 
2008). Perhaps, the combination of ROS-generating drug with an inhibitor to 
suppress redox-adaptation could be a better approach to the management of 
cancer malignancy. Despite various lines of evidence from studies in cancer 
cells, little is known about the role of TQ-induced ROS in the animal model. 
Further studies in animals are needed to elucidate the effect of TQ on ROS 




4.6  The role of p38 MAPK in the anticancer activities of TQ 
The family of MAPKs plays important roles in many cell functions, such as 
cell proliferation, apoptosis and cell survival (Johnson and Lapadat, 2002). 
Our data showed that TQ could increase the phosphorylation of ERK, JNK 
and p38 MAPK in MCF-7 cells. TQ was also shown to specifically increase 
the phosphorylation of p38 in MCF-7 and MDA-MB-231 cells, whereby these 
increases could be reversed by p38-specific inhibitor, SB203580. At the 
present, there are a few papers reporting the effect of TQ on MAPKs pathway. 
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TQ was shown to induce the phosphorylation of ERK and JNK, but not p38, in 
DLD-1 colon cancer cells (El-Najjar et al., 2010). In contrast, there is a report 
showed that TQ could induce both JNK and p38 phosphorylation in 
FG/COLO357 pancreatic cancer cells (Torres et al., 2010). Although the same 
paper elucidated that the JNK and p38 activations were mediated via TQ-
induced Mucin-4 down-regulation, the role of JNK and p38 activations in the 
anticancer activities of TQ was not explained (Torres et al., 2010).   
Our results showed that p38 activation induced by TQ involved in the 
cytotoxic and pro-apoptotic effects of TQ, as these effects could be abrogated 
by p38-specific inhibitor and p38 siRNA gene silencing. In contrast, TQ could 
induce ERK and JNK phosphorylation in DLD-1 cells, and the inhibition of 
these MAPKs by the treatment of ERK (PD98059) and JNK (SP600125) 
specific inhibitors could sensitize the cancer cells to TQ-induced apoptosis 
(El-Najjar et al., 2010). This was supported by another study showing that 
although TQ could induce JNK phosphorylation in PC-3 prostate cancer cells, 
pre-treatment with JNK-specific inhibitor (SP600125) could not prevent cell 
death from TQ. Therefore, even though TQ was shown to induce the 
phosphorylation of ERK and JNK, the results from these papers suggested that 
these activations might serve as a survival mechanism in response to the 
cytotoxicity of TQ. Nevertheless, more experiments should be conducted on 
different cell lines to explain this point in a greater detail.   
The role of p38 in apoptosis has been reported in many cancer cell types, thus 
making it a possible tumor suppressor. The p38 protein can bind to p53 to 
form a complex, which in turn, enhancing the phosphorylation of p53 (She et 
al., 2000). Pharmacological inhibition and gene knockdown of p38 could 
prevent p53-mediated apoptosis (She et al., 2001). Interestingly, despite the 
role of p38 in apoptosis, there are data showed that p38 activation might 
involve in cancer cell invasion (Yong et al., 2009). This is largely due to the 
regulatory role of p38 in MMP protein family which is involved in tumor 
invasion and metastasis. For example, p38 was found to phosphorylate heat-
shock protein 27, which in turn, activating MMP-2 for PC3 prostate cancer 
cell invasion (Xu et al., 2006). The relationship of p38 and MMP-2 was also 
reported in other carcinomas including human melanoma cells (Denkert et al., 
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2002) and patient metastatic ovarian carcinoma (Davidson et al., 2003). In 
addition to MMP-2, p38 pathway was also found to regulate the expression of 
MMP-9 in human ovarian epithelial carcinoma cells (SKOV-3 and CaOV-3) 
(Zhou et al., 2007) and human squamous carcinoma cells (UM-SCC-1) 
(Simon et al., 2001). Moreover, MMP-1 and MMP-13 were found to be 
regulated by p38 in transformed human epidermal keratinocytes (Johansson et 
al., 2000). 
Our data showed that GW9662 was able to enhance TQ-induced p38 
activation in MCF-7 cells, but not MDA-MB-231 cells. On the other hand, 
SB203580 treatment was found to increase the protein expression of PPAR-γ 
in MCF-7 cells. These results suggested that TQ-induced activation of p38 and 
PPAR-γ might antagonize each other. A recent study reported that 
rosiglitazone, a PPAR-γ agonist, could inhibit p38 phosphorylation in 
microglia (He et al., 2012). This was supported by another paper showing that 
T33, a novel PPAR-γ/α agonist, was able to reduce TNF-α, COX-2, and p-p38 
levels, whereby these reductions could be reversed by the GW9662 (Wang et 
al., 2011c). In addition, KR-62980, a novel PPAR-γ ligand, was shown to 
reduce ERK1/2 and p38 phosphorylation in endothelial cells (Kim et al., 2011). 
Pre-treatment with BADGE, a PPAR-γ antagonist, could reverse the effects of 
KR-62980 (Kim et al., 2011). Although they are PPAR-γ agonists in the same 
family, rosiglitazone, but not pioglitazone, was found to deactivate various 
MAPKs including ERK1/2, JNK and p38 in renal podocytes. However, 
PPAR-γ activation does not always lead to the suppression of p38. For 
example, troglitazone was found to increase the level of p-p38 in 786-O, Caki-
2 and ACHN human renal cell carcinoma cells, whereby these increases could 
be blocked by the p38-specific inhibitor, SB202190 (Fujita et al., 2011). Thus, 
depending on the cell types and ligands used, the activation of MAPKs might 
work differently (Gardner et al., 2005). As such more data are needed to 
explain the interaction between PPAR-γ and p38 in the mechanism of action 
of TQ. For example, conditional p38 knockdown can be used to study the 




4.7  The antitumor effect of TQ in animal models 
Animal models provide better extrapolation and estimation to the effects of a 
drug candidate in the human body, and thus, the data from animal works are 
always a pre-requisite to bring a drug to future clinical setting. In the present, 
different administrations of TQ in mouse model were reported, including 5 
mg/kg i.p. (Gali-Muhtasib et al., 2008b), 20 mg/kg i.p. (Kaseb et al., 2007), 20 
mg/kg s.c. (Kaseb et al., 2007; Jafri et al., 2010), 5 mg/kg intratumoral 
(Ivankovic et al., 2006), 3 mg/mouse intragastric (Banerjee et al., 2009), and 
100 µg/ml in drinking water (Badary et al., 1999). Since no pharmacokinetic 
study of TQ is available, the dose of TQ used in our animal model was 
determined after justification of several TQ’s reports. We were interested to 
investigate the systemic therapeutic effect of TQ, thus intraperitoneal injection 
was selected. Two doses of TQ, 4 mg/kg and 8 mg/kg, were selected after 
justification from two papers in the literature (Gali-Muhtasib et al., 2008b; 
Kaseb et al., 2007).  
In this project, our data showed that TQ was able to suppress the growth of 
breast tumor xenograft and, when combined with doxorubicin, produced 
greater inhibitory effect. TQ was found to suppress cell proliferation and 
induce apoptosis in breast tumor tissues as shown by decreased Ki67-positive 
and increased TUNEL-positive cells, respectively. The expression of anti-
apoptotic genes such as survivin, XIAP, Bcl-xL and Bcl-2 in tumor tissues 
were inhibited in TQ treatment groups. Moreover, p-p38 expression in TQ 
treatment groups was increased with no change in p38 expression, which was 
in line with the findings in cell line. PPAR-γ expression was suppressed in TQ 
treatment groups, in line with the findings in MDA-MB-231 cell line.    
The antitumor effect of TQ and its possible molecular mechanisms have been 
shown in other types of tumor xenograft such as lung (Jafri et al., 2010), colon 
(Gali-Muhtasib et al., 2008b), prostate (Kaseb et al., 2007) and pancreas 
cancer (Banerjee et al., 2009). For example, NF-κB, a transcription factor 
which might be responsible for cisplatin resistance, was down-regulated by 
TQ treatment in NCI-H460 cells-induced lung tumor xenograft (Jafri et al., 
2010). This is supported by another study showing that TQ was able to 
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suppress NF-κB and its-regulated molecules (such as XIAP, survivin and 
VEGF) in SaOS-2-induced osteosarcoma tumors (Peng et al., 2013). In 
addition, TQ treatment was found to down-regulate androgen receptor, E2F-1 
and cyclin A in C4-2B cells-induced prostate tumor xenograft (Kaseb et al., 
2007). On the other hand, by drinking TQ-added water after benzo(a)pyrene 
induction, forestomach tumor incidence and multiplicity could be reduced 
(Badary et al., 1999). A recent study showed that TQ could prevent 1,2-
dimethyl-hydrazine-induced oxidative stress and colon tumor development 
(Jrah-Harzallah et al., 2013). The combination of TQ and chemotherapeutic 
agents has been reported to cause greater inhibitory effect not only in cancer 
cells but also in animal models, for example combined with cisplatin in lung 
tumor xenograft (Jafri et al., 2010), as well as combined with gemcitabine or 
oxaliplatin in pancreatic tumor xenograft (Banerjee et al., 2009).  
In addition to antitumor effect, TQ is able to protect against the toxicity caused 
by various chemotherapeutic agents. For example, TQ was found to ameliorate 
the nephrotoxicity caused by cisplatin in mice and rats (Badary et al., 1997). In 
addition, doxorubicin-induced nephropathy in rats could be reduced by TQ 
treatment (Badary et al., 2000). Moreover, cardio-toxicity, the major concern 
of doxorubicin regimen, could be ameliorated by TQ treatment without 
compromising its therapeutic efficacy (Al-Shabanah et al., 1998). The similar 
protective activity was also observed in cyclophosphamide-induced 
cardiotoxicity in rats (Nagi et al., 2010). The increase in quinone reductase 
and glutathione transferase in mice liver after TQ treatment might explain the 
protective effect of TQ against drug toxicities (Nagi and Almakki, 2009). If 
the toxicities caused by chemotherapeutic agents are able to be ameliorated by 
TQ, clinicians are more willing to increase the dose of these agents for greater 
efficacy. These results suggest the possible complementary role of TQ in 
combination regimen to target resistant cancer.  
The effect of TQ on anti-oxidant enzymes/molecules was investigated in this 
project. Our results showed that TQ treatment increased catalase, SOD and 
glutathione levels in mouse liver tissues. However, we are not certain whether 
the increase of these anti-oxidant enzymes/molecules was due to the direct 
effect of TQ or in response to the ROS-inducing effect of TQ. Although this 
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study and many other papers reported the induction effect of TQ treatment on 
ROS production together with its role in apoptosis, there are studies reporting 
the efficacy of TQ’s antioxidant effect. For example, TQ could act as a potent 
superoxide radical and free radical scavenger at micromolar and nanomolar 
range of concentrations, respectively (Mansour et al., 2002). This was 
supported by another report showing that TQ could act as a potent superoxide 
anion scavenger and inhibited iron-dependent microsomal lipid peroxidation 
in a dose-dependent manner (Badary et al., 2003). On the other hand, TQ was 
shown to reverse the decrease of catalase, glutathione-S-transferase, 
glutathione peroxidase and reduced glutathione in the kidney and liver tissues 
of streptozotocin-diabetic rats (Sankaranarayanan and Pari, 2011). This was 
supported by another study showing that TQ was able to reverse the decrease 
in the activity and mRNA expression of catalase, glutathione peroxidase and 
glutathione-S-transferase in the liver tissues of diethylnitrosamine-induced rats 
(Sayed-Ahmed et al., 2010). The increase of glutathione after TQ treatment 
could improve the experimental allergic encephalomyelitis in female Lewis rat 
(Mohamed et al., 2003). However, these studies did not explain whether the 
changes in the level of anti-oxidant enzymes/molecules were the direct effect 
of TQ. Interestingly, there is a report showed that TQ did not cause any 
significant change in the glutathione level in mouse hepatic, cardiac and 
kidney tissues (Mansour et al., 2002). Taken together, the role of TQ as an 
anti-oxidant or pro-oxidant drug needs further evaluation especially in the 
animal model. Thus, well-designed animal models are needed to elucidate the 
role of TQ in different diseases such as inflammatory disorder and cancer. For 
example, the oxidation status in TQ-treated tumor tissues can be studied to 
investigate whether the pro-oxidant or anti-oxidant effect of TQ is responsible 
for its antitumor action. Moreover, tumor-induced mice can be co-treated with 
TQ and anti-oxidant drug to investigate whether ROS induction is playing a 
role in TQ’s antitumor effect.    
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5  CONCLUSION  
 
The studies in breast cancer cells and in the breast tumor xenograft mouse 
model demonstrated that TQ is a potential anticancer agent. In addition to 
growth inhibition and pro-apoptotic effects, TQ was found to inhibit the 
migration and invasion of breast cancer cells. Moreover, the inhibitory effect 
of TQ might be mediated via PPAR-γ, ROS and p38 MAPK pathways. TQ 
was able to induce PPAR-γ activity specifically. This was later found to be 
responsible for the suppression of survivin. The effect of TQ on ROS 
induction was also noted. By using NAC, an antioxidant agent, to block ROS 
induction, the anticancer effects of TQ could be abrogated. Moreover, TQ-
induced suppression of anti-apoptotic genes, such as survivin, XIAP, Bcl-2 
and Bcl-xL, were able to be reversed by NAC. On the other hand, TQ was 
found to induce p38 activation which could be reversed by p38-specific 
inhibitor. The TQ-induced p38 activation was later found to be responsible for 
TQ’s cytotoxic and pro-apoptotic effects. Moreover, ROS production was 
found to be the upstream regulator of PPAR-γ and p38 in the mechanistic 
action of TQ. TQ was also found to suppress breast tumor growth in nude 
mice and this suppression was greater when combined with doxorubicin. 
Decreased cell proliferation and increased apoptosis were observed in breast 
tumor xenograft after TQ treatment. TQ was found to increase the hepatic 
level of catalase, SOD and glutathione, which might explain its ROS-inducing 
effect. Overall, the effects of TQ in breast carcinoma are summarized in 
Figure 5.1.  
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6 FUTURE DIRECTIONS 
 
Collectively, other studies and our data suggest that TQ is a multi-targeted 
anticancer drug. The concern regarding off-target effect which may result in 
side effect(s) need to be addressed. A well-designed toxicological study 
should be conducted to evaluate the safety of this drug in humans. Moreover, 
the studies on the bioavailability and pharmacokinetic of TQ are also 
important to determine how the body handles TQ. TQ has low solubility due 
to high hydrophobicity, whereby this will resulting in low bioavailability. 
There is a study showed that TQ could be loaded in liposomes to increase 
bioavailability (Odeh et al., 2012). This strategy however require more data 
from animal models.  
This project has identified the interesting effects of TQ, whereby it induced 
the expression of PPAR-γ in MCF-7 cells, but reduced the expression of 
PPAR-γ in MDA-MB-231 cells. This difference should be explained in a 
greater detail, possibly by genetic approaches such as PPAR-γ overexpression 
or PPAR-γ shRNA gene knockdown in MCF-7 and MDA-MB-231 cell lines 
follow by experiments with TQ. In addition, co-treatment of TQ with PPAR-γ 
ligand/inhibitor in MDA-MB-231 cells can be carried out to study the role of 
PPAR-γ in the antitumor effect of TQ.  
Several studies have shown that the anticancer activities of TQ in various 
cancer cell lines were mediated via the increase in ROS level. However, this 
mechanism of action still remains unexplained in the in vivo model. Since 
ROS induction could be the upstream regulator in the anticancer mechanism 
of TQ, it is important to evaluate the regulatory role of ROS on proteins such 
as p53, p73, p38, PPAR-γ, NF-κB, STAT3 and PTEN, which had been 
reported to be involved in TQ-induced apoptosis.    
The combination of TQ and chemotherapeutic agents has been shown to 
produce greater efficacy in several tumor xenograft models, including lung 
and pancreas (Woo et al., 2012). However, more studies are needed to 
examine the effects of different combination with TQ on various tumor types, 
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such as liver and colon cancer. In addition, toxicological studies are warranted 
to evaluate the safety of such combinations.  
Numerous studies have demonstrated the anti-inflammatory effect of TQ in 
different disease models including asthma (El Gazzar et al., 2006a; El Gazzar 
et al., 2006b), arthritis (Budancamanak et al., 2006; Tekeoglu et al., 2006; 
Vaillancourt et al., 2011) and diabetes (Pari and Sankaranarayanan, 2009). TQ 
was shown to attenuate allergic airways by suppressing several Th1 cytokines, 
including IL-4, IL-5 and IL-13, and infiltration of eosinophil into the airways 
(El Gazzar et al., 2006b). Moreover, TQ could inhibit 5-lipoxygenase and 
leukotriene C4 synthase in human blood cells (Mansour and Tornhamre, 2004). 
It was also shown that TQ could inhibit cyclooxygenase-2 protein expression 
and prostaglandin E2 production in HPAC pancreatic cancer cells (Banerjee et 
al., 2009). Since excessive inflammation lead to the initiation of 
carcinogenesis, TQ as an anti-inflammatory agent may protect against cancer 
development. Further studies can be carried out to investigate whether TQ is 
able to prevent carcinogenesis by regulating body immune system.     
The anticancer activities of TQ have been reported in many pre-clinical 
studies mainly in cancer cell lines and tumor xenograft mice. There are limited 
numbers of clinical trial conducted with TQ to date. A phase I trial reported 
that TQ did not cause significant systemic toxicity in adult patients with solid 
tumors or hematological malignancies, and the human body could tolerate a 
dose of TQ up to 2600 mg per day (Al-Amri and Bamosa, 2009). However, 
the same study also reported that there was no anticancer effect observed in 
these patients. Since the pharmacokinetic of TQ remains unknown, the effect 
of TQ in the human body is unpredictable because we do not know how the 
body absorbs and handles TQ. On the other hand, a double blinded crossover 
clinical trial has shown that TQ was able to exhibit antiepileptic effects in 
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